

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

12 EUROPEAN PATENT APPLICATION

21 Application number: 84103030.7

22 Date of filing: 20.03.84

51 Int. Cl.³: C 07 D 401/04
 C 07 D 403/04, C 07 D 413/04
 C 07 D 417/04, A 61 K 31/53
 //C07D253/06

30 Priority: 22.03.83 GB 8307831
 18.04.83 GB 8310437

43 Date of publication of application:
 24.10.84 Bulletin 84/43

84 Designated Contracting States:
 AT BE CH DE FR GB IT LI LU NL SE

71 Applicant: Fujisawa Pharmaceutical Co., Ltd.
 3, Doshomachi 4-chome Higashi-ku
 Osaka-shi, Osaka 541(JP)

72 Inventor: Teraji, Tsutomu
 No. 20-6, Kofudai 6-chome
 Toyono-cho Toyono-gun Osaka(JP)

72 Inventor: Shiokawa, Youichi
 No. 814, Hozumidai 9-chome
 Ibaraki-shi Osaka(JP)


72 Inventor: Okumura, Kazuo
 No. 13-7, Harayamadai 4-chome
 Sakai-shi Osaka(JP)

72 Inventor: Sato, Yoshinari
 No. 1-9, Higashihagoromo 7-chome
 Takaishi-shi Osaka(JP)

74 Representative: Türk, Dietmar, Dr. rer. nat. et al,
 Redies, Redies, Türk & Gilla Patentanwälte
 Brucknerstrasse 20
 D-4000 Düsseldorf 13(DE)

54 Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same.

57 New triazine derivatives represented by the formula:



wherein

R¹ is a 1, 2, 3, 4-tetrahydroquinolyl,
 2-oxo-1, 2, 3, 4-tetrahydroquinolyl,
 2-oxo-1, 2-dihydroquinolyl,
 indolyl,
 2-oxoindolyl,
 benzothiazolyl,
 2-oxobenzothiazolyl,
 3,4-dihydro-1H-2, 1-benzothiazinyl in which the S atom
 optionally oxidized, or
 3-oxo-2, 3-dihydro-4H-1, 4-benzoxazinyl, each of which
 may have one or more substituent(s) selected from lower
 alkyl, hydroxy (lower) alkyl, lower alkylamino, lower alkanoyl,

cyclic lower alkanoyl, lower alkoxy (lower) alkyl, lower
 alkylamino (lower) alkanoyl, benzyl, benzyloxy (lower)-alkyl,
 lower alkoxy carbonyl (lower) alkyl and

4-(2-hydroxyethyl) piperazin-1-yl-carbonylmethyl;
 R² is a hydrogen, lower alkenyl, benzyl, carboxy (lower)-
 alkyl or lower alkoxy carbonyl (lower) alkyl;

R³ and R⁴, which may be the same or different, are each
 hydrogen or lower alkyl or together represent a bond;
*provided that when R¹ is 2-oxo-1, 2, 3, 4-tetrahydroquinolyl
 which is unsubstituted or substituted by a lower alkyl, then, R⁴
 is a hydrogen or R² is a lower alkenyl, benzyl, carboxy (lower)
 alkyl or lower alkoxy carbonyl (lower) alkyl; and pharmaceuti-
 cally acceptable salt thereof, which are useful in the treatment
 of hypertension, thrombosis and ulcer in human beings and
 animals.*

TRIAZINE DERIVATIVES, PROCESSES FOR
PREPARATION THEREOF AND PHARMACEUTICAL
COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel triazine derivatives and pharmaceutically acceptable salts thereof. More particularly, it relates to novel, 6-substituted 1,2,4-triazin-3(2H)-one and pharmaceutically acceptable salts thereof which have antihypertensive activity, inhibitory activity on platelet aggregation and anti-ulcer activity, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a method of using the same therapeutically in the treatment of hypertension, thrombosis and ulcer in human beings and animals.

Accordingly, one object of this invention is to provide novel 6-substituted-1,2,4-triazin-3(2H)-one and pharmaceutically acceptable salts thereof, which are useful as an antihypertensive agent, antithrombotic agent and antiulcer drug.


Another object of this invention is to provide

processes for preparation of said triazine derivatives and pharmaceutically acceptable salts thereof.

A further object of this invention is to provide pharmaceutical composition comprising, as an active ingredient, said triazine derivative or its pharmaceutically acceptable salt.

Still further object of this invention is to provide a method of using said triazine derivative or its pharmaceutically acceptable salt in the treatment of hypertension, thrombosis and ulcer in human beings and animals.


With regard to the state of the arts in this field, for example, the European Patent Publication Number 0052442 describes the following 1,2,4-triazin-3(2H)-one compounds.



(wherein R is nitro, cyano, amino, methylureido, acetamido, carboxy, lower alkyl, carbamoyl optionally substituted lower alkyl, thiocarbamoyl or morpholinocarbonyl)

It has now been found that certain 6-substituted-1,2,4-triazin-3(2H)-one compounds which have not been described in any of the references have strong antihypertensive activity, inhibitory activity on platelet aggregation and antiulcer activity.

The object compounds of the present invention include the ones represented by the following formula [I].



[I]

5 wherein

10 R^1 is a 1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 indolyl,
 2-oxoindolinyl,
 benzothiazolyl,
 2-oxobenzothiazolinyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in which the
 15 S atom being optionally oxidized, or
 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
 each of which may have one or more substituent(s)
 selected from lower alkyl, hydroxy(lower)alkyl,
 lower alkylamino, lower alkanoyl, cyclic lower
 20 alkanoyl, lower alkoxy(lower)alkyl,
 lower alkylamino(lower)alkanoyl, benzyl, benzyloxy-
 (lower)alkyl, lower alkoxy carbonyl(lower)alkyl and
 4-(2-hydroxyethyl)piperazin-1-yl-carbonylmethyl;
 R^2 is a hydrogen, lower alkenyl, benzyl, carboxy(lower)-
 25 alkyl or lower alkoxy carbonyl(lower)alkyl;
 R^3 and R^4 , which may be the same or different, are each
 hydrogen or lower alkyl or together represent
 a bond;

30 provided that when R^1 is 2-oxo-1,2,3,4-tetrahydroquinolyl
 which is unsubstituted or substituted by a lower alkyl,
then, R^4 is a hydrogen or R^2 is a lower alkenyl, benzyl,
 carboxy(lower)alkyl or lower alkoxy carbonyl(lower)alkyl;
 and pharmaceutically acceptable salt thereof.

35 With regard to the object compound [I], it should
 be understood that the compounds [I] include all of the

possible optical and/or geometrical isomers due to the asymmetric carbon atom(s) and/or double bond(s) in their molecules.

5 Suitable illustrations and examples of the above definitions are explained in the following.

 The term "lower" is intended to mean a group having 1 to 6 carbon atoms, unless otherwise indicated.

10 Suitable "lower alkyl" may include straight or branched lower alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like, and preferably the ones having 1 to 4 carbon atom(s)

15 Suitable "hydroxy(lower)alkyl" may include hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, 6-hydroxyethyl and the like.

20 Suitable "lower alkylamino" may include mono- or di-(lower)alkylamino such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, pentylamino, hexylamino, dimethylamino, diethylamino, methylethylamino, dipropylamino, methylpropylamino, dibutylamino, dipentylamino, dihexylamino and the like.

25 Suitable "lower alkanoyl" may include straight or branched acyclic lower alkanoyl such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and the like, and more preferably the ones having 1 to 4 carbon atom(s).

30 Suitable "cyclic lower alkanoyl" may include cyclopropanecarbonyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl and the like, and more preferably the ones having 4 to 7 carbon atoms.

25 Suitable "lower alkoxy(lower)alkyl" may include methoxymethyl, 1-methoxyethyl, 2-methoxyethyl, ethoxymethyl, 2-methoxypropyl, 3-methoxypropyl, 2-ethoxypropyl, 3-ethoxypropyl, isopropoxymethyl, t-butoxymethyl,

4-methoxybutyl, 5-methoxypentyl, 6-methoxyhexyl and the like.

Suitable "lower alkylamino(lower)alkanoyl" may include the aforementioned lower alkanoyl groups being substituted with a mono- or di-(lower alkyl)amino group such as methylamino, dimethylamino, ethylamino, diethylamino, methylethylamino, propylamino, isopropylamino, isopropylmethylamino, butylamino, pentylamino, hexylamino and the like.

More preferably, "lower alkylamino(lower)alkanoyl" may include methylaminoacetyl, dimethylaminoacetyl, ethylaminoacetyl, diethylaminoacetyl, isopropylaminoacetyl, 3-dimethylaminopropionyl and the like.

Suitable "benzyloxy(lower)alkyl" may include the aforementioned lower alkyl groups being substituted with a benzyloxy group at any carbon of the alkyl group.

More preferably, "benzyloxy(lower)alkyl" may include benzyloxymethyl, 2-benzyloxyethyl, 1-benzyloxypropyl, 2-benzyloxypropyl, 3-benzyloxypropyl, 4-benzyloxybutyl, 5-benzyloxypentyl, 6-benzyloxyhexyl and the like.

Suitable "lower alkoxycarbonyl(lower)alkyl" may include the aforementioned lower alkyl groups being substituted with a lower alkoxycarbonyl group such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, and the like.

More preferably, "lower alkoxycarbonyl(lower)alkyl" may include methoxycarbonylmethyl, 2-methoxycarbonylethyl, ethoxycarbonylmethyl, 2-ethoxycarbonylethyl, 2-propoxycarbonylethyl, 2-butoxycarbonylethyl and the like.

Suitable "lower alkenyl" may include vinyl, 1-propenyl, allyl, isopropenyl, 1-, 2- or 3-butenyl, 1,3-butadienyl, 3-methyl-2-butenyl, 1-, 2-, 3-, 4- or 5-hexenyl and the like.

Suitable "carboxy(lower)alkyl" may include the

aforementioned lower alkyl group being substituted with a carboxy group at any carbon of the alkyl group.

More preferable "carboxy(lower)alkyl" may include carboxymethyl, 2-carboxyethyl, 1-methyl-2-carboxyethyl,
5 carboxybutyl and the like.

10

"1,2,3,4-Tetrahydroquinolyl,
2-oxo-1,2,3,4-tetrahydroquinolyl,
15 2-oxo-1,2-dihydroquinolyl,
indolyl,
2-oxoindolinyl,
benzothiazolyl,
2-oxobenzothiazolyl,
20 3,4-dihydro-1H-2,1-benzothiazinyl in which the S atom
being optionally oxidized, and
3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl" for R¹ may have one
or more substituent(s) selected from the aforementioned
lower alkyl, hydroxy(lower)alkyl, lower alkylamino,
25 lower alkanoyl, cyclic lower alkanoyl, lower alkoxy(lower)-
alkyl, lower alkylamino(lower)alkanoyl, benzyl,
benzyloxy(lower)alkyl, lower alkoxycarbonyl(lower)alkyl
and 4-(2-hydroxyethyl)piperazin-1-yl-carbonylmethyl.

Suitable "1,2,3,4-tetrahydroquinolyl" may include
30 1,2,3,4-tetrahydroquinolin-5 or 6 or 7 or 8-yl compounds.

Suitable "2-oxo-1,2,3,4-tetrahydroquinolyl" may
include 2-oxo-1,2,3,4-tetrahydroquinolin-5 or 6 or 7 or 8-
yl compounds

Suitable "2-oxo-1,2-dihydroquinolyl" may include
35 2-oxo-1,2-dihydroquinolin-5 or 6 or 7 or 8-yl compounds.


Suitable "indolyl" may include 4 or 5 or 6 or 7-indolyl compounds.

Suitable "2-oxoindolinyl" may include 2-oxoindolin-4 or 5 or 6 or 7-yl compounds.

5 Suitable "benzothiazolyl" may include benzothiazol-4 or 5 or 6 or 7-yl compounds.

Suitable "2-oxobenzothiazolinyl" may include 2-oxobenzothiazolin-4 or 5 or 6 or 7-yl compounds.

10 Suitable "3,4-dihydro-1H-2,1-benzothiazinyl in which the S atom being optionally oxidized" can be represented as the formula :



wherein n is an integer of 0 to 2.

20

Suitable "3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl" may include 3-oxo-2,3-dihydro-4H-1,4-benzoxazin-5 or 6 or 7 or 8-yl compounds


25 Suitable pharmaceutically acceptable salts of the object compound [I] are conventional non-toxic salts and may include an acid addition salt such as an inorganic acid addition salt (e.g., chloride, bromide, sulfate, phosphate, etc.), an organic acid addition salt
30 (e.g., oxalate, maleate, lactate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.) or a salt with an amino acid (e.g. arginine salt, aspartic acid salt, glutamic acid salt, etc.), a salt with a base such as alkali metal salt (e.g., sodium
35 salt, potassium salt, etc.), alkaline earth metal salt

(e.g. calcium salt, magnesium salt, etc.) and the like.


The object compounds [I] of the present invention can be prepared by the following processes.

5


Process 1




Process 2




Process 3




Process 4




Process 5




Process 6




Process 7




Process 8




Process 9




Process 10



Process 11



Process 12



10 (wherein R^1 , R^2 , R^3 and R^4 are each as defined above;
 R_a^1 is a 1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 indolyl,
 15 2-oxoindolyl,
 benzothiazolyl,
 2-oxobenzothiazolyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in which the S
 atom being optionally oxidized, or
 20 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
 each of which has at least one substituent
 selected from lower alkanoyl, cyclic lower alkanoyl
 and benzyloxy(lower)alkyl;
 R_b^1 is a 1,2,3,4-tetrahydroquinolyl,
 25 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 indolyl,
 2-oxoindolyl,
 benzothiazolyl,
 30 2-oxobenzothiazolyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in which the
 S atom being optionally oxidized, or
 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
 each of which may be substituted with a
 35 hydroxy(lower)alkyl;

R_C^1 is a 1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 indolyl,
 5 2-oxoindolinyl,
 benzothiazolyl,
 2-oxobenzothiazolinyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in which the
 S atom being optionally oxidized, or
 10 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl;
 R_D^1 is a 1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 indolyl,
 15 2-oxoindolinyl,
 benzothiazolyl,
 2-oxobenzothiazolinyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in which the
 S atom being optionally oxidized, or
 20 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
 each of which has at least one substituent
 selected from lower alkanoyl, cyclic lower
 alkanoyl, and lower alkylamino(lower)alkanoyl;
 R_E^1 is a 1,2,3,4-tetrahydroquinolyl,
 25 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 indolyl,
 2-oxoindolinyl,
 benzothiazolyl,
 30 2-oxobenzothiazolinyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in which the
 S atom being optionally oxidized, or
 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
 each of which is substituted with a lower alkyl,
 35 hydroxy(lower)alkyl, lower alkoxy(lower)alkyl,

benzyl, benzyloxy(lower)alkyl, lower
alkoxycarbonyl(lower)alkyl and
4-(2-hydroxyethyl)piperazin-1-yl-carbonylmethyl;
5 R_f^1 is a 1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2-dihydroquinolyl,
indolyl,
2-oxoindolyl,
10 benzothiazolyl,
2-oxobenzothiazolyl,
3,4-dihydro-1H-2,1-benzothiazinyl in which the
S atom being optionally oxidized, or
3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
15 each of which is substituted with a lower
alkoxycarbonyl(lower)alkyl;
 R_g^1 is a 1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2-dihydroquinolyl,
indolyl,
20 2-oxoindolyl,
benzothiazolyl,
2-oxobenzothiazolyl,
3,4-dihydro-1H-2,1-benzothiazinyl in which the
S atom being optionally oxidized, or
25 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
each of which is substituted with a
4-(2-hydroxyethyl)piperazin-1-yl-carbonylmethyl;
 R_a^2 is lower alkenyl, benzyl, carboxy(lower)alkyl or
lower alkoxycarbonyl(lower)alkyl;
30 R_b^2 is lower alkoxycarbonyl(lower)alkyl;
 R_c^2 is carboxy(lower)alkyl;
 R_a^3 is lower alkyl;
 R_a^4 is hydrogen or lower alkyl;
35

R⁵ is hydrogen or lower alkyl;
R⁶ is hydrogen or lower alkyl;
R⁷ is lower alkylamino;
Y is acid residue; and
5 Z is a leaving group.

Suitable "acid residue" may include halogen (e.g. fluorine, chlorine, bromine, iodine), acyloxy (e.g. benzenesulfonyloxy, tosyloxy, etc.) and the like.
10

Suitable "leaving group" may include mercapto, lower alkylthio (e.g. methylthio, ethylthio, isopropylthio, etc.), carboxy(lower)alkylthio (e.g. carboxymethylthio, 2-carboxyethylthio, 3-carboxypropylthio, 3-carboxybutylthio, etc.) and the like.
15

The other definitions of each symbols are exemplified the ones as described hereinbefore.

20 Process 1

The compound [Ia] and its salt can be prepared by reacting a compound [II] or its salt with a compound [III] or its salt.

Suitable salt of the compound [II] may be exemplified beforementioned alkali metal salt, alkaline earth metal salt, and the like.
25

The present reaction is usually carried out in a conventional solvent such as water, alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), N,N-dimethylformamide, or any other solvent which does not adversely influence the reaction.
30

Though the reaction temperature is not critical the reaction may preferably be carried out at ambient temperature or under warming or heating.

35 The reaction may be conducted in the presence or

absence of alkali metal halide (e.g. sodium iodide, potassium iodide, etc.), and the like.

Process 2

5 The compound [Ib] and its salt can be prepared by reducing a compound [Ia] or its salt.

10 The reduction can be carried out by a conventional method, for example, by using a reducing agent such as lithium borohydride, sodium borohydride, potassium borohydride, sodium cyanoborohydride or lithium aluminium
15 hydride etc.; by chemical reduction using metal (e.g., zinc, iron, copper, etc.) and acid (e.g., hydrochloric acid, sulfuric acid, etc.), or metal (e.g., sodium, lithium, zinc, etc.) and base (e.g. ammonia, sodium
20 hydroxide, etc.); or by catalytic reduction. The catalytic reduction is usually carried out in the presence of a conventional catalyst, such as Raney nickel, palladium, platinum, rhodium, copper, etc. preferably
at ambient temperature under atmospheric pressure and in a conventional solvent. The reduction using a
reducing agent is usually carried out in a conventional solvent, preferably a polar solvent, such as water, alcohol, and the like.

25 The present reaction can be conducted under cooling or slightly elevated temperature, and optionally in the presence of a base such as sodium hydroxide, sodium carbonate, potassium carbonate, etc.

Process 3


30 The compound [Ic] and its salt can be prepared by treating a compound [IV] or its salt with a base and then reducing the reaction product.

35 Suitable base to be used in the first step may include alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal

hydroxide (e.g. calcium hydroxide, etc.), and the like.

The treatment of the compound [IV] or its salt with a base can be preferably conducted in a polar solvent such as alcohol (e.g., methanol, ethanol, propanol, etc.), water, ether (e.g., dimethyl ether, diethyl ether, tetrahydrofuran, dioxane, etc.), aromatic solvent (e.g., benzene, toluene, xylene, etc.).

The reaction product obtained in the initial step is the compound of the following formula [II] or its salt.



(wherein R^1 and R_a^4 are each as defined above, and M is an alkali metal or alkaline earth metal ion)

Said compound [II] and its salt can be optionally isolated and purified, but they can be used in the second step without isolation or purification, also.

The reduction of the compound [II] or its salt in the second step can be carried out according to a similar manner to that of Process 2.

Process 4

The compound [Ie] and its salt can be prepared by subjecting a compound [Id] or its salt to solvolysis.

The solvolysis is carried out in accordance with a conventional method such as hydrolysis, and the like. Among these methods, hydrolysis in the presence of a base or an acid is one of the common and preferable ones. Suitable base is alkali metal hydroxide, alkaline earth metal hydroxide, or the like.

The present reaction is usually carried out in a

solvent such as water, alcohol and the like. The reaction temperature is not critical and the reaction can be carried out at ambient temperature or under warming or heating.

5

Process 5

The object compound [Ig] and its salt can be prepared by reacting a compound [If] or its salt with an alkylating agent. The preferred alkylating agent may be a lower alkylhalide (e.g., lower alkylchloride, lower alkylbromide, lower alkyliodide), lower alkylsulfate (e.g., dimethylsulfate etc.), lower alkane sulfonate (e.g., lower alkyl mesylate, lower alkyl tosylate etc.) and the like. The reaction is usually carried out in a solvent such as alcohol (e.g., methanol, ethanol, propanol, etc.), at room temperature or under warming, and preferably in the presence of a base such as alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), alkali metal alkoxide (e.g., sodium methoxide, potassium methoxide, etc.), alkali metal hydride (e.g. sodium hydride, potassium hydride, etc.) and the like.

10

15

20

Process 6

The compound [Ii] and its salt can be prepared by subjecting the compound [Ih] or its salt to an elimination reaction of the protective group. The elimination reaction of the protective group can be conducted by a solvolysis (e.g. hydrolysis, aminolysis, alcoholysis, etc.), hydrogenolysis, or the like according to a kind of the protective group.

30

Among these methods, in case of the protective group is an acyl group such as a lower alkanoyl, solvolysis in the presence of a base or an acid is one of the common and preferable methods. More preferably, aminolysis using hydrazine or ammonia is convenient.

35

In case of the protective group is a ar(lower)alkyl group, hydrolysis in the presence of an acid is one of the preferable methods.

Suitable acid may include hydrogen halide (e.g. hydrogen iodide, hydrogen bromide, etc.), boron trihalide (e.g. boron tribromide, boron trichloride, etc.) and the like. The present reaction can be conducted under cooling to heating in a conventional solvent which does not adversely influence the reaction such as water, alcohol, dichloromethane, chloroform and the like.

Process 7

The compound [Ij] and its salt can be prepared by subjecting a compound [V] or its salt to a reaction called "Fischer Indole Synthesis" or chemically equivalent thereto.

Suitable salt of the compound [V] may include a beforementioned alkali metal salt, alkaline earth metal salt and the like.

This reaction is usually carried out in a conventional solvent which does not adversely influence the reaction such as beforementioned alcohol, ethylene-glycohol, benzene, toluene, xylene, and the like. Though the reaction temperature is not critical, the reaction is preferably carried out under warming or heating. The present reaction can optionally be conducted in the presence of a catalyst such as heavy metal halide (e.g. zinc chloride, cuprous chloride, etc.), organic or inorganic acid (e.g., sulfuric acid, hydrochloric acid, acetic acid, etc.) and the like.

Process 8

The compound [Ik] and its salt can be prepared by subjecting a compound [VI] or its salt to a cyclization reaction.

Suitable salt of the compound [VI] may include
aforementioned alkali metal salt, alkaline earth metal
salt and the like.

5 The cyclization reaction can be conducted by
treating a compound [VI] or its salt with thionyl halide
(e.g. thionyl chloride, thionyl bromide, etc.) and then
treating the reaction product with an acid (e.g.
hydrochloric acid, sulfuric acid, acetic acid etc.) and
the like. The present reaction can be conducted in
10 a conventional solvent which does not adversely
influence the reaction such as chloroform or aromatic
solvent (e.g. benzene, toluene, xylene, etc.) and the
like. The reaction temperature is not critical, but
the reaction is preferably carried out under warming or
15 heating.

Process 9

The compound [I₂] and its salt can be prepared by
treating a compound [VII] or its salt with hydrazine
20 hydrate under warming or heating.

This reaction can be carried out in a conventional
solvent which does not adversely influence the reaction
such as water, aforementioned alcohol, aromatic solvent
(e.g. benzene, toluene, xylene etc.), N,N-dimethyl-
25 formamide and the like.

Process 10

The compound [In] and its salt can be prepared by
acylation a compound [Im] or its salt with an acylating
30 agent. The acylating agent is an acid derivative which
include an acid halide (e.g. acid chloride, acid bromide,
etc.), an acid anhydride such as a mixed acid anhydride
with an acid (e.g., phosphoric acid, dialkylphosphorous
acid, sulfurous acid, sulfuric acid, alkyl carbonate,
35 aliphatic carboxylic acid, aromatic carboxylic acid, etc.),

an activated acid amide with a heterocyclic compound (e.g., imidazole, triazole, etc.), an activated ester (e.g. cyanomethyl ester, 2,4-dinitrophenylester, etc.), isocyanate, isothiocyanate and the like.

5 The acylation is preferably carried out in the presence of a base in a solvent under cooling or heating according to a conventional way.

10 Suitable base may include an amine (e.g., triethylamine, pyridine, N,N-dimethylaniline, etc.), an aforementioned alkali metal hydroxide, an alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), alkali metal bicarbonate (e.g. sodium bicarbonate, etc.), a salt of an organic acid (e.g., sodium acetate, etc.) and the like. In case that the base is liquid,
15 the base can be used as a solvent.

 Suitable solvent may include acetonitrile, chloroform, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, or any other solvent or an optional mixture thereof which does not adversely influence the reaction.

20 Further, when the acylating agent is used in a form of the free acid or its salt in this reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as a carbodiimide compound, a ketenimine compound, a phosphorous compound
25 and the like.

Process 11

 The compound [Ip] and its salt can be prepared by alkylating a compound [Im] or its salt in a conventional
30 way.

 Suitable alkylating agent may be lower alkyl halide such as lower alkyl chloride (e.g., propylchloride, butylchloride, etc.), lower alkyl bromide (e.g., methylbromide, ethylbromide, propylbromide, butylbromide, etc.), lower
35 ethylbromide, propylbromide, butylbromide, etc.), lower

alkyl iodide (e.g. methyl iodide, ethyl iodide, propyl iodide, etc.); lower alkyl sulfate (e.g., dimethyl sulfate, diethyl sulfate, etc.), lower alkanesulfonate such as lower alkyl mesylate (e.g., methyl mesylate, ethyl mesylate, etc.), lower alkyl tosylate (e.g., methyl tosylate, ethyl tosylate, etc.), a combination of aldehyde or ketone compound and a reducing agent, and the like. Benzyl, Benzyloxy(lower)alkyl, lower alkoxy(lower)-alkyl and lower alkoxy carbonyl(lower)alkyl compounds are also obtained by using an alkylating agent having benzyl, benzyloxy, lower alkoxy or lower alkoxy carbonyl group.

Preferred alkylating agent for methylation is a combination of formaldehyde and a reducing agent as mentioned in process 2. The reaction can be conducted in a suitable solvent as mentioned in process 2 at ambient temperature or an elevated temperature in a presence or absence of an acid (e.g., acetic acid, p-toluene sulfonic acid, etc.).

20 Process 12

The compound [Ir] and its salt can be prepared by reacting a compound [Iq] or its salt with 1-(2-hydroxy-ethyl)piperazin compound. This reaction can be carried out in a conventional solvent such as alcohol, aromatic solvent, chloroform etc. This reaction can preferably be conducted in the presence of an acid or base mentioned in process 2 above.

The starting compounds of the above processes contain new and known compounds and the new compounds can be prepared by the methods as shown in the Examples or the methods chemically equivalent thereto.

The salts of the starting compounds are exemplified the ones as the salts of compounds [I].

The object compounds [I] obtained in the above Process 1 to 12 can be isolated and purified in a

conventional manner, for example, extraction, precipitation, fractional chromatography, fractional crystallization, recrystallization, and the like.

5 The object compound [I] thus prepared can be transformed into a pharmaceutically acceptable salt by a conventional method, if desired.

In case that the object compound [I] is a mixture of the optical isomers, optical resolution can optionally be conducted by conventional method.

10 The following antihypertensive test data, inhibitory activity test data on platelet aggregation and antiulcer test data show that the compound [I] of the present invention exhibit antihypertensive activity, inhibitory activity on platelet aggregation and antiulcer
15 activity, and are useful as antihypertensive agents for treating hypertension and as antithrombotic agents for treating thrombosis and also as antiulcer drugs for treating ulcer in animals and human being.

20 Test method A

Five-week old male Wister rats were uninephrectomized under anesthesia. Deoxycorticosterone acetate (DOCA) (30 mg/kg), suspended in peanut oil, was injected subcutaneously twice a week and 1% saline was substituted
25 for the drinking water. Animals with mean blood pressure 150-200 mmHg were used for experiment between 5 and 7 weeks after surgery.

The test compounds were administered intraperitoneally or orally. Blood pressure was measured at the femoral
30 artery by means of a pressure transducer and recorded as electrically integrated values of mean arterial pressure.

Test results A

35 Mean ratios of maximum decrease of blood pressure (mmHg) were shown in the following table.

Test Compound (Example No.)	Dose	Effect Max (%)
8 - (4)	a	15
8 - (4)	b	49
10 - (5)	b	40
10 - (6)	a	33
10 - (6)	b	57
12 - (3)	b	58
12 - (3)	a	40
15	b	68

* a : The test compound were administered orally in dose of 0.1 mg/kg.

* b : The test compound were administered orally in a dose of 1 mg/kg.

Furthermore, the above mentioned antihypertensive activity of these compounds were observed to continue more than 6 hours.

Test Method B

Platelet rich plasma (PRP) which contains $6.5-7.5 \times 10^8$ platelet/ml was prepared from rabbit blood. To the 200 μ l of PRP, 5 μ l of calcium chloride (1 mM) and 50 μ l of pH 7.4 Tris-acetate solution (5 mM) containing 120mM NaCl and test compound were added successively, and then

stirred for 2 min. at 37°C. To the solution, 5 µl of
adenosine diphosphate (ADP) (2.5 µM) or collagen
(2.5 µg/ml) was added as an aggregation inducer.
Aggregation was measured by using an aggregometer
5 (NKK HEMA TRACER 1). ID₅₀ was shown in Table 2.

Test results B

10	Test Compound (Example No.)	ID ₅₀ (Mol)	
		ADP	Collagen
	8 - (4)	3.6×10^{-7}	2.4×10^{-7}
15	9 - (4)	4.6×10^{-6}	2.7×10^{-6}
	10 - (5)	1.4×10^{-6}	5.4×10^{-7}
	10 - (6)	1.3×10^{-6}	4.7×10^{-7}
20	11 - (3)	3.7×10^{-6}	1.9×10^{-6}
	11 - (4)	5.6×10^{-5}	2.2×10^{-5}
25	12 - (3)	6.7×10^{-8}	4.8×10^{-8}
	13	1.6×10^{-7}	3.4×10^{-8}
	14	2.5×10^{-7}	8.1×10^{-8}
30	15	5.8×10^{-6}	2.0×10^{-6}

Test methods C

Sprague-Dawley rats weighing about 200 g were used.
35 Each animal was immobilized in a small cage and put in

a water bath allowing to respire. The temperature of the water bath kept at 22°C. The test compound was administered orally just before the immobilization. Seven hours later, the animals were sacrificed and their stomachs were removed. The stomach was then fixed with 2% formalin. The area of ulcers was measured for each animal. The mean area (mm²) in the test animals was compared with that in the control animals and inhibition effect (%) were calculated.

Test results C

Test Compound (Example No.)	Dose	Effect (%)
8 - (4)	c	68.0
8 - (4)	d	80.0

* c : The test compound was administered orally in dose of 10 mg/kg.

* d : The test compound was administered orally in dose of 32 mg/kg.

As being apparent from the above test results, the object compounds [I] of the present invention are useful for antihypertensive medicines, antithrombotic medicines and antiulcer medicines.

The effective ingredient may usually be administered with a dose of 0.01 mg/kg to 500 mg/kg, 1 to 4 times a day in preparations such as tablet, granule, powder, capsule, syrup, injection, suppository and the like. However, the above dosage may be increased or decreased according to the age, weight or conditions of the patient or the administering method.

The pharmaceutical preparation may be prepared in a conventional manner.

The following Examples are given only for the purpose of illustrating the present invention in more detail.

5

10


15

20

25

30

35



Example 1

(1) A mixture of 6-(2-hydroxyiminopropionyl)-1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline (1 g), thiosemicarbazide (0.48g), methanol (10 ml), water (5 ml) and acetic acid (0.1 ml) was refluxed for 13 hours with stirring. After cooling, the resulting precipitates were collected by filtration, washed successively with ethanol, water and ethanol, and then dried to give 0.34 g of 6-(2-hydroxyimino-1-thiosemicarbazonopropyl)-1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline.

NMR (DMSO- d_6 , δ) : 2.14 (3H, s), 2.4-3.1 (4H, m), 3.25 (3H, s), 7.0-7.3 (3H, m), 8.07 (1H, b.s.), 8.47 (1H, s), 8.5 (1H, b.s.), 11.68 (1H, s)

(2) A mixture of the above obtained compound (5.65 g) of (1) and potassium carbonate (7.35 g) in water (42 ml) was refluxed for 5 hours with stirring. After cooling, the mixture was filtered by suction and then sodium chloroacetate (3.09 g) was added to the filtrate at ambient temperature with stirring. After 15 hours, the mixture was washed with ethyl acetate and then acidified with diluted hydrochloric acid. The resultant precipitates were collected by filtration, washed with water, and dried to give 4.76 g of 3-carboxymethylthio-5-methyl-6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-triazine.

IR (Nujol) : 3050 (broad), 1740, 1645 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.53 (3H, s), Ca. 2.5-2.79

(2H, m), 2.83-3.1 (2H, m), 3.31 (3H, s), 4.11 (2H, s), 7.26 (1H, d, $J=8\text{Hz}$), 7.59 (1H, d, $J=2\text{Hz}$), 7.64 (1H, d, $J=2, 8\text{Hz}$)

(3) A solution of potassium hydroxide (13.74 g) in water (36 ml) was added to a solution of the above obtained compound (21.1 g) of Example 1-(2) in methanol (50 ml)

and heated at 60° for 4 hours with stirring. The mixture was concentrated to a small volume and cooled. The resultant precipitate was collected by filtration, washed with methanol, and dried in air to give potassium 5-methyl-6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-triazin-3-oxide (15.07 g).

NMR (DMSO-d₆, δ) : 2.16 (3H, s), 2.35-3.05 (4H, m)
3.35 (3H, s), 7.10 (1H, d, J=8.5Hz),
7.26-7.55 (2H, m).

(4) Allyl bromide (1.95 g) was added to a mixture of the above obtained compound (3.4 g) of Example 1-(3) and potassium iodide (1.47 g) in N,N-dimethylformamide (8 ml) and stirred for 60 hours at room temperature. To the mixture was added water and extracted with a mixture of chloroform and methanol. The extract was washed successively with water, an aqueous solution of sodium hydroxide, and water and then purified by column chromatography on silica gel (100 g) with ethyl acetate as an eluent to give 2-allyl-5-methyl-6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-triazin-3(2H)-one (1.35 g).

The above obtained product (1.34 g) was dissolved in methanol (10 ml) and sodium borohydride (0.16 g) was added to it. After being stirred for 30 minutes at room temperature, the solution was evaporated in vacuo. To the residue was added water and extracted with chloroform. The extract was dried over magnesium sulfate and evaporated in vacuo to give 2-allyl-5-methyl-6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-4,5-dihydro-1,2,4-triazin-3(2H)-one (1.11 g).

NMR (CDCl₃, δ) : 1.37 (3H, d, J=6.5Hz), 2.45-3.17 (4H, m), 3.36 (3H, s), 4.42 (2H, b, d, J=5Hz),
4.68 (1H, d, q, J=3, 6.5Hz), 5.07-5.47 (2H, m),
5.68-6.30 (1H, m), 6.44-6.60 (1H, m), 6.97 (1H, d, J=9Hz), 7.41-7.67 (2H, m).

Example 2

(1) A solution of ethyl bromoacetate (2.66 g) in N,N-dimethylformamide (4 ml) was added dropwise to a solution of potassium 5-methyl-6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-triazin-3-oxide (4.39 g) in the same solvent (28 ml) and stirred for 30 minutes at room temperature. To the solution was added water and extracted with chloroform. The extract was washed with water and chromatographed on silica gel (150 g) with a mixture of ethyl acetate, and benzene (1:1) and then ethyl acetate as eluents. The eluate with ethyl acetate was concentrated to a small volume. The resultant precipitate was collected by filtration, washed with a mixture of ethyl acetate and diisopropyl ether, and dried to give 2-ethoxycarbonylmethyl-5-methyl-6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-triazin-3(2H)-one (1.81 g).

NMR (CDCl₃, δ) : 1.30 (3H, t, J=7Hz), 2.53 (3H, s), 2.6-3.2 (4H, m), 3.39 (3H, s), 4.27 (2H, q, J=7Hz), 4.87 (2H, s), 7.06 (1H, d, J=8Hz), 7.25-7.56 (2H, m).

(2) Sodium borohydride (0.2 g) was added portionwise to a solution of the above obtained compound (1.8 g) of Example 2-(1) in ethanol (20 ml) under ice cooling. After being stirred for 30 minutes, the solution was evaporated in vacuo and the residue was acidified with diluted hydrochloric acid under ice cooling. The resultant precipitate was collected by filtration, washed with water, and dissolved in chloroform. The solution was purified by column chromatography on silica gel (30 g) with ethyl acetate as an eluent to give 2-ethoxycarbonylmethyl-5-methyl-6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-4,5-dihydro-1,2,4-triazin-3(2H)-one (1.19 g).

NMR (CDCl₃, δ) : 1.29 (3H, t, J=7Hz), 1.45 (3H, d, J=7Hz), 2.47-3.16 (4H, m), 3.36 (3H, s), 4.24 (2H, q, J=7Hz), 4.57 (2H, s), 4.70 (1H, d, q, J=3, 7Hz),

methyl-1,2,4-triazin-3(2H)-one (4.47 g).

NMR (CDCl_3 , δ) : 2.47 (3H, s), 2.47-3.20 (4H, m),
3.40 (3H, s), 5.31 (2H, s), 6.98-7.65 (8H, m)

5 (2) 6-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-
2-benzyl-5-methyl-1,2,4-triazin-3(2H)-one (2.21 g) was
reacted with sodium borohydride (0.23 g) according to a
similar manner to that of Example 2-(2).

10 The reaction mixture was evaporated in vacuo. To
the residue was added 10% hydrochloric acid and extracted
with ethyl acetate. The extract was washed with water,
dried over magnesium sulfate, and evaporated in vacuo to
give 2-benzyl-5-methyl-6-(1-methyl-2-oxo-1,2,3,4-
15 tetrahydroquinolin-6-yl)-4,5-dihydro-1,2,4-triazin-3(2H)-
one (2.57 g).

NMR (DMSO-d_6 , δ) : 1.22 (3H, d, $J=6.5\text{Hz}$),
2.33-3.10 (4H, m), 3.22 (3H, s), 4.69 (1H; q;
 $J=3, 6.5\text{Hz}$), 4.86 (2H, s), 6.97-7.43 (7H, m),
7.43-7.70 (2H, m)

20

(3) Methyl iodide (1.96 g) was added to a mixture of
the above obtained compound (2.53 g) of Example 3-(2)
and sodium hydride (0.218 g) in *N,N*-dimethylformamide
(3 ml), and heated at 50° for 1 hour with stirring. To
25 the mixture was added water and extracted with ethyl
acetate. The extract was dried over magnesium sulfate
and evaporated in vacuo. The residue was chromatographed
on silica gel (30 g) with ethyl acetate as an eluent.
The eluate was evaporated in vacuo and the residual solid
30 was washed successively with diisopropyl ether and ethyl
acetate to give 2-benzyl-4,5-dimethyl-6-(1-methyl-2-oxo-
1,2,3,4-tetrahydroquinolin-6-yl)-4,5-dihydro-1,2,4-
triazin-5(2H)-one (1.39 g).

35 NMR (CDCl_3 , δ) : 1.32 (3H, d, $J=6.7\text{Hz}$), 2.45-3.16
(4H, m), 3.04 (3H, s), 3.36 (3H, s),

4.48 (1H, q, J=6.7Hz), 4.86 (1H, d, J=15Hz),
5.16 (1H, d, J=15Hz), 6.96 (1H, d, J=9Hz),
7.15-7.66 (7H, m)

5 Example 4

(1) 1-(2-Benzyloxyethyl)-2-oxo-6-propionyl-1,2,3,4-tetrahydroquinoline (32.4 g) was dissolved in methylene chloride (97 ml) and the solution was saturated with hydrogen chloride. To the stirred solution was added
10 dropwise iso-amyl nitrite (13.5 g) over 0.5 hour. After stirring for 1 hour, the reaction mixture was evaporated in vacuo and the oily residue was dissolved in diethyl ether and extracted with 10% aqueous solution of sodium hydroxide. The extract was washed with diethyl ether,
15 acidified with diluted hydrochloric acid, and extracted with chloroform. The extract was washed with water, dried over magnesium sulfate, and evaporated in vacuo. The oily residue was triturated with benzene to give 1-(2-benzyloxyethyl)-6-(2-hydroxyiminopropionyl)-2-oxo-1,2,3,4-tetrahydroquinoline (9.19 g).
20

IR (Nujol) : 3250 (shoulder), 3160, 3020, 1640,
1600 cm⁻¹

NMR (CDCl₃, δ) : 2.15 (3H, s), 2.3-3.1 (4H, m),
3.70 (2H, t, J=5.5Hz), 4.14 (2H, t, J=5.5Hz),
25 4.47 (2H, s), 7.0-7.5 (6H, m), 7.7-8.0 (2H, m),
Ca. 10.0 (1H, b.s.)

(2) 1-(2-Benzyloxyethyl)-6-(2-hydroxyimino-1-thiosemicarbazopropyl)-2-oxo-1,2,3,4-tetrahydroquinoline
30 (8.99 g) (isomeric mixture) was obtained from the above object compound (8.98 g) of Example 4-(1) according to a similar manner to that of Example 1-(1).

IR (Nujol) : 3410, 3300, 3160, 1665, 1600 cm⁻¹

NMR (DMSO-d₆, δ) : 1.96 (s) } (3H), Ca. 2.4-3.1 (4H, m),
2.17 (s)
35 3.63 (2H, b.t., J=5Hz), 4.15 (2H; b.t., J=5Hz)

4.47 (s)} (2H), 6.92-7.5 (3H, m), 7.3 (5H, s),
4.50 (s)}
Ca. 8.0 (b.s.)} (1H), 8.13 (b.s.)} (2H),
7.66 (b.s.)}
12.1 (s)} (1H)
11.69 (s)}

5

(3) A mixture of the above obtained compound (10.1 g) of Example 4-(2), potassium carbonate (7.03 g) and water (57 ml) was refluxed for 3.5 hours with stirring, and the reaction mixture was treated with activated charcoal and filtered by suction. To the filtrate was added dropwise methyl iodide (3.91 g) with stirring, and the stirring was continued for 15 minutes at ambient temperature. The reaction mixture was extracted with chloroform. The extract was washed with water, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (60 g) with chloroform as an eluent to give an oil of 6-[1-(2-benzyloxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]-5-methyl-3-methylthio-1,2,4-triazine (6.81 g).

10

15

20

IR (film/NaCl) : 1675, 1610 cm^{-1}
NMR (CDCl_3 , δ) : 2.59 (3H, s), 2.72 (3H, s),
Ca. 2.5-3.2 (4H, m), 3.79 (2H, t, $J=5.2\text{Hz}$),
4.23 (2H, t, $J=5.2\text{Hz}$), 4.56 (2H, s), 7.29
(5H, s), 7.3-7.7 (3H, m)

25

(4) A mixture of the above obtained compound (6.62 g) of Example 4-(3) in 10% aqueous solution of potassium hydroxide (33 ml) and methanol (65 ml) was heated at 60°C for 10.5 hours with stirring and allowed at room temperature. To the solution was added sodium borohydride (0.8 g), stirred for 1.5 hours at room temperature and acidified with conc. hydrochloric acid under ice cooling. After addition of water thereto, the reaction mixture was extracted with chloroform and the extract was washed

30

35

with water, dried over magnesium sulfate, and evaporated in vacuo. The oily residue was triturated with acetone to give 6-[1-(2-benzyloxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (3.92 g).

IR (Nujol) : 3220, 3100, 1685, 1645, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21 (3H, d, $J=6.4\text{Hz}$),

Ca. 2.4-2.8 (2H, m), 2.8-3.2 (2H, m),

3.62 (2H, t, $J=5.4\text{Hz}$), 4.13 (2H, t, $J=5.4\text{Hz}$),

4.48 (2H, s), Ca. 4.4-4.9 (1H, m), Ca. 7.1-7.8 (4H, m), 7.26 (5H, s), 9.93 (1H, d, $J=2\text{Hz}$)

(5) A solution of boron tribromide (4.59 g) in methylenechloride (5 ml) was added dropwise to a stirred suspension of 6-[1-(2-benzyloxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (2.38 g) in methylene chloride (200 ml) at -40°C over a period of 10 minutes. After being stirred for 40 minutes at the same temperature, methanol (0.6 ml) was added to the suspension and evaporated in vacuo. The residue was dissolved in n-butanol, washed with brine, and evaporated in vacuo. The residual solid was washed with ethyl acetate and recrystallized from methanol to give 6-[1-(2-hydroxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.91 g), mp 237 to 243°C .

IR (Nujol) : 3300, 3200, 1665, 1635, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21 (3H, d, $J=6.4\text{Hz}$),

Ca. 2.3-2.4 (2H, m), 2.4-3.1 (2H, m),

3.69 (2H, b.d., $J=5.5\text{Hz}$), 3.91 (2H, b.d.,

$J=5.5\text{Hz}$), 4.64 (1H; d, q; $J=3, 6.4\text{Hz}$),

7.24 (1H, d, $J=9.4\text{Hz}$), 7.39 (1H; b.s.),

7.55 (2H, b.s.), 9.91 (1H, d, $J=1.6\text{Hz}$)

Anal. Calcd. for $\text{C}_{15}\text{H}_{18}\text{N}_4\text{O}_3$:

C, 59.59; H, 6.00; N, 18.57

Found : C, 59.33; H, 6.02; N, 17.98

Example 5

(1) 6-(2-Hydroxyiminopropionyl)-4-methyl-2,3-dihydro-4H-1,4-benzoxazin-3-one (5.71 g) was obtained from 4-methyl-6-propionyl-2,3-dihydro-4H-1,4-benzoxazin-3-one (10.05 g) according to a similar manner to that of Example 4-(1).

IR (Nujol) : 3360, 1670, 1636 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.03 (3H, s), 3.31 (3H, s),
4.75 (2H, s), 7.06 (1H, d, $J=9.4\text{Hz}$),
7.5-7.74 (2H, m), 12.21 (1H, s)

(2) 6-(2-Hydroxyimino-1-thiosemicarbazonopropyl)-4-methyl-2,3-dihydro-4H-1,4-benzoxazin-3-one (6.28 g) was obtained from the above obtained compound (5.71 g) of Example 5-(1) according to a similar manner to that of Example 1-(1).

IR (Nujol) : 3340, 3250, 3160, 1687, 1622 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.94 (s) } (3H), 3.36 (s) } (3H),
2.15 (s) } (3H), 3.25 (s) } (3H),
4.71 (2H, s), 6.7-7.6 (3H, m), 8.13 (1H, b.s.),
8.62 (2H, b.s.), 12.15 (s) } (1H)
11.69 (s) }

(3) 6-(4-Methyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-6-yl)-5-methyl-3-methylthio-1,2,4-triazine (2.1 g) was obtained from the above obtained compound (6.28 g) of Example 5-(2) according to a similar manner to that of Example 4-(3).

IR (Nujol) : 1678 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.52 (3H, s), 2.66 (3H, s),
3.32 (3H, s), 4.73 (2H, s), 7.0-7.5 (3H, m)

(4) 6-(4-Methyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.79 g) was obtained from the above obtained compound (2.1 g) of Example 5-(3) according to a similar manner to

that of Example 4-(4).

mp : 286 to 290°C (recrystallized from 70% aqueous ethanol)

5 NMR (DMSO- d_6 , δ) : 1.22 (3H, d, $J=6.8$ Hz), 3.32 (3H, 4.68 (1H, m), 4.71 (2H, s), 7.03 (1H, d, $J=8.2$ Hz 7.2-7.6 (3H, m), 9.96 (1H, b.s.)

IR (Nujol) : 3250, 3050, 1696, 1661 cm^{-1}

Anal. Calcd. for $\text{C}_{13}\text{H}_{14}\text{N}_4\text{O}_3$:

C, 56.93; H, 5.14; N, 20.43

10 Found : C, 57.19; H, 5.13; N, 20.56

Example 6

(1) An isomeric mixture of 4'-acetylamino-2-hydroxyiminopropiophenone thiosemicarbazone (1.7 g) was
15 obtained from 4'-acetylamino-2-hydroxyiminopropiophenone (1.87 g) according to a similar manner to that of Example 1-(1).

20 NMR (DMSO- d_6 , δ) : 2.08 (3H, s), 2.17 (3H, s), 7.18 (2H, d, $J=8$ Hz), 7.73 (2H, d, $J=8$ Hz), 8.13 (1H, b.s.), 8.63 (2H, b.s.), 9.10 (b.s.) } (1H), 11.69 (s) } (1H)
10.23 (b.s.) } (1H), 12.26 (s) } (1H)

(2) A mixture of the above object compound (34.74 g)
25 of the Example 6-(1) and potassium carbonate (35.88 g) in water (300 ml) was refluxed for 3 hours under stirring. After cooling, sodium chloroacetate (20.6 g) was added to the solution at ambient temperature and stirring was continued for 2 hours. The aqueous solution was washed
30 with chloroform, acidified with hydrochloric acid, and allowed to stand over night in a refrigerator. The precipitates were collected by filtration, washed with water and dried to give 6-(4-acetylamino-phenyl)-3-carboxymethylthio-5-methyl-1,2,4-triazine (16.7 g).

35

NMR (DMSO- d_6 , δ) : 2.10 (3H, s), Ca. 2.5 (3H, s),
3.96 (2H, s), 7.58 (2H, d, $J=8\text{Hz}$),
7.77 (2H, d, $J=8\text{Hz}$), 10.35 (1H, s)

5 (3) 6-(4-Acetylamino-phenyl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (6.12 g) was obtained from the above object compound (10.61 g) of Example 6-(2) according to a similar manner to that of Example 4-(4).

mp : 272 to 273°C (recrystallized from 60% ethanol)

10 NMR (DMSO- d_6 , δ) : 1.22 (3H, d, $J=7\text{Hz}$), 2.08 (3H, s),
4.64 (1H, m), 7.43 (1H, b.s.), 7.68 (4H, s),
9.96 (1H, d, $J=2\text{Hz}$), 10.10 (1H, s)

Anal. Calcd. for $C_{12}H_{14}N_4O_2 \cdot H_2O$:

C, 54.54; H, 6.10; N, 21.20

15 Found : C, 54.87; H, 6.00; N, 21.45

(4) A mixture of the above object compound (3.35 g) of the Example 6-(3) and 100% hydrazin hydrate (33 ml) was heated at 120° for 2 hours under stirring and allowed to stand overnight at room temperature. The precipitate was collected by filtration, washed with methanol, and dried. The filtrate was evaporated in vacuo and the residue was triturated with ethanol to give the second crop. The combined crude products were recrystallized from 60% aqueous ethanol to give 6-(4-aminophenyl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (1.61 g).

mp : 248 to 249.5°C

30 NMR (DMSO- d_6 , δ) : 1.16 (3H, d, $J=7\text{Hz}$), 4.52 (1H, d, q; $J=3.5, 7\text{Hz}$), 5.41 (2H, s), 6.58 (2H, d, $J=8\text{Hz}$), 7.23 (1H, b.s.), 7.42 (2H, d, $J=8\text{Hz}$), 9.67 (1H, d, $J=2\text{Hz}$)

Anal. Calcd. for $C_{10}H_{12}N_4O$:

C, 58.81; H, 5.92; N, 27.44

Found : C, 58.64; H, 5.96; N, 27.33

(5) A solution of sodium nitrite (3.6 g) in water (10 ml) was added dropwise to a solution of 6-(4-aminophenyl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (9.8 g), concentrated hydrochloric acid (10 ml) and water (30 ml) at 0°C. After stirring for 0.5 hours, a solution of stannous chloride dihydrate (43.12 g) in conc. hydrochloric acid (43 ml) was added thereto at 0°C. After stirring for 2 hours, the mixture was made alkaline with an aqueous solution of sodium hydroxide and the resultant precipitates were collected by filtration and washed with water. The crude product was dissolved in 10% hydrochloric acid under warming, and then allowed to stand at room temperature. The precipitates were collected by filtration and then dissolved in water. The aqueous solution was washed with ethyl acetate, treated with activated charcoal, and made alkaline with an aqueous solution of sodium hydroxide. The resultant precipitates were collected by filtration, washed with water, and recrystallized from 10% hydrochloric acid to give 6-(4-hydrazinophenyl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one hydrochloride (3.2 g).

mp : 235°C (dec.)

NMR (DMSO-d₆, δ) : 1.19 (3H, d, J=7.5Hz), 4.45 (1H; d, q; J=3, 7.5Hz), 7.02 (2H, d, J=8.5Hz), 7.26-7.50 (1H, b.m.), 7.65 (2H, d, J=8.5Hz), 7.9-9.0 (1H, b.m.), 9.8-10.0 (1H, b.m.), 9.7-10.9 (2H, b.m.)

And further, 6-(4-hydrazinophenyl)-5-methyl-4,5-dihydro-1,2,4-triazine-3(2H)-one (1.35 g) was obtained by treating the above mother liquid with an aqueous solution of sodium hydroxide.

NMR (DMSO-d₆, δ) : 1.19 (3H, d, J=7Hz), 3.93-4.18 (2H, b.m.), 4.54 (1H, d, q: J=4, 7Hz), 6.77 (2H, d, J=9Hz), 6.95-7.14 (1H, b.m.),

7.14-7.34 (1H, b.m.), 7.49 (2H, d, J=9Hz),
9.57-9.80 (1H, b.m.)

(6) A mixture of 6-(4-hydrazinophenyl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (3.11 g) and 2-butanone (3.07 g) in ethanol (50 ml) and a saturated solution of hydrogen chloride in ethanol (1 drop) was refluxed for 2 hours with stirring. The mixture was filtered and the filtrate was evaporated in vacuo to give a residue. The residual solid was washed with ethyl acetate to give isomeric mixture of 6-(4-sec-butylidenehydrazinophenyl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (3.12 g).
NMR (DMSO-d₆, δ) : 1.05 (3H, t, J=7.5Hz),
1.18 (3H, d, J=7Hz), 1.86 (s) } (3H),
1.92 (s)
2.26 (q, J=7.5) } (2H), 4.55 (1H; d, q; J=3, 7Hz),
2.34 (q, J=7.5)
7.07 (2H, d, J=8.8Hz), 7.10-7.45 (1H, m),
7.56 (2H, d, J=8.8Hz), 8.89 (s) } (1H),
8.97 (s)
9.64-9.83 (1H, m)

(7) A mixture of the above object compound (3.1 g) of (6) in ethylene glycol (20 ml) was refluxed for 13 hours with stirring and then allowed to room temperature. To the solution was added water and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and chromatographed on silica gel (125 g) with ethyl acetate as an eluent. The eluates were evaporated and the residual solid was recrystallized from aqueous ethanol to give 6-(2,3-dimethylindol-5-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (1.39 g).

mp : 292 to 296°C

NMR (DMSO-d₆, δ) : 1.25 (3H, d, J=6.5Hz), 2.17 (3H, s), 2.31 (3H, s), 4.74 (1H; d, q; J=3.5, 6.5Hz), 7.14-7.60 (3H, m), 7.67-7.80 (1H, m), 9.73-9.86 (1H, m),

10.66-10.90 (1H, m)

Anal. Calcd. for $C_{14}H_{16}N_4O$:

C, 65.61; H, 6.25; N, 21.86

Found : C, 65.14; H, 6.17; N, 22.05

5

Example 7

(1) Methyl isothiocyanate (0.788 g) was added to a solution of 6-(4-aminophenyl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (2 g) in N,N-dimethylformamide (20 ml) and the mixture was stirred for 4 hours at 110°C. After cooling, the mixture was treated with activated charcoal and evaporated in vacuo. The residual solid was washed with water and dried to give 6-[4-(3-methylthioureido)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (2.7 g).

15

IR (Nujol) : 3215, 3060, 1680, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21 (3H, d, $J=6.6\text{Hz}$),

2.53 (3H, d, $J=2\text{Hz}$), 4.63 (1H; d, q; $J=2, 6.6\text{Hz}$),

7.1-8.1 (6H, m), 9.68 (1H, b.s.), 9.91 (1H, b.s.)

20

(2) A mixture of the above obtained compound (1.5 g) of Example 7-(1) and thionyl chloride (7 ml) was heated at 50° for 4 hours with stirring and then evaporated in vacuo. To the residue was added 10% hydrochloric acid (30 ml) heated at 60° for 30 minutes, and filtered by suction. The filtrate was washed with chloroform and made alkaline with concentrated ammonium hydroxide under ice cooling. The resultant precipitate was collected by filtration washed with water, and recrystallized from a mixture of chloroform and methanol.

30

The above obtained product was purified by column chromatography on silica gel (40 g) with a mixture of chloroform and methanol (15:1) as an eluent to give 6-(2-methylaminobenzothiazol-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.34 g).

35

mp : 290 to 295°C

IR (Nujol) : 3210, 3090, 1690 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.27 (3H, d, $J=6.4\text{Hz}$),
2.98 (3H, d, $J=4\text{Hz}$), 4.66 (1H, m), 7.41 (1H, b.s.),
5 7.43 (1H, d, $J=8.8\text{Hz}$), 7.66 (1H; d,d; $J=1.6$,
8.8Hz), 8.03 (1H, b.s.), 8.09 (1H, d, $J=1.6\text{Hz}$),
9.91 (1H, b.s.)

Mass : m/e 275 (M^+)

10 Example 8

(1) To a stirred solution of 1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin (17.7 g) and aluminum chloride (44.5 g) in 1,2-dichloroethane (26 ml) was added dropwise a solution of 2-phthalimidoacetyl chloride (25 g) in 1,2-dichloroethane (45 ml). The reaction mixture was stirred for 6 hours at 85°C and then 22 hours at 60°C. After cooling, the mixture was poured into ice water and extracted with chloroform. The extract was washed successively with water, an aqueous solution of sodium bicarbonate and water, dried and evaporated. The residue was triturated with ethyl acetate and the resultant precipitates were collected by filtration, washed with ethyl acetate and dried to give 18.51 g of 1-methyl-2-oxo-6-phthalimidoacetyl-1,2,3,4-tetrahydroquinoline.

25 IR (Nujol) : 1770 (s), 1720, 1685, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 2.4-3.2 (4H, m), 3.35 (3H, s),
5.07 (2H, s), 7.04 (1H, d; $J=9.0\text{Hz}$),
7.5-8.1 (6H, m)

30 (2) A mixture of the above obtained compound (18.4 g) of Example 8-(1), conc. hydrochloric acid (36 ml) in acetic acid (72 ml) was refluxed for 6 hours. Conc. hydrochloric acid (72 ml) was added thereto and then further refluxed for 8.5 hours. After cooling, the
35 reaction mixture was evaporated and triturated with ethanol.

The resulting precipitates were collected by filtration, washed with ethanol and dried to give 9.12 g of 6-aminoacetyl-1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline hydrochloride.

5 IR (Nujol) : 3450, 3350, 1680, 1660, 1600 cm^{-1}
NMR (DMSO- d_6 , δ) : 2.5-3.2 (4H, m), 3.26 (3H, s),
4.54 (2H, b.s.), 7.23 (1H, d, $J=9.0\text{Hz}$),
7.8-8.13 (2H, m), 8.66 (2H, b.s.)

10 (3) To a stirred solution of the above obtained compound (4.0 g) in dichloromethane (40 ml) was added dropwise triethylamine (3.18 g) and then a solution of ethyl chloroformate (1.74 g) in dichloromethane (2 ml). After stirring for 20 minutes, the mixture was washed
15 with diluted hydrochloric acid and brine, dried over magnesium sulfate, and evaporated. The residue was washed with diethyl ether to give 3.36 g of 6-ethoxycarbonylaminoacetyl-1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline.

20 IR (Nujol) : 3320, 1685 (shoulder), 1675, 1600 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.17 (3H, t, $J=7\text{Hz}$),
Ca. 2.5-3.2 (4H, m), 3.28 (3H, s),
4.02 (2H, q, $J=7.0\text{Hz}$), 4.46 (2H, d, $J=5.8\text{Hz}$),
7.1-7.4 (2H, m), 7.7-8.1 (2H, m)

25

(4) A mixture of the above obtained compound (2.98 g) of Example 8-(3), water (30 ml), ethanol (3 ml) and 100% hydrazine hydrate (5 ml) was refluxed for 15.5 hours. After cooling, resultant precipitates were collected by
30 filtration, washed with water, and recrystallized from a mixture of N,N-dimethylformamide and water to give 1.74 g of 6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-4,5-dihydro-1,2,4-triazin-3(2H)-one.

mp : 283 to 287°C (dec.)

35 IR (Nujol) : 3220, 3080, 1705, 1645 cm^{-1}

NMR (DMSO-d₆, δ) : 2.3-3.2 (4H, m), 3.26 (3H, s),
4.25 (2H, d, J=1.4Hz), 7.06 (1H, d, J=9.2Hz),
7.17 (1H, s), 7.4-7.6 (2H, m), 9.78 (1H, s)

Anal. Calcd. for C₁₃H₁₄N₄O₂ :

C: 60.46; H: 5.46; N: 21.69

Found : C: 60.31; H: 5.36; N: 21.73

Example 9

(1) 1-Methyl-2-indolinone (34.0 g) and 2-phthalimido-acetyl chloride (37.3 g) was reacted according to a similar manner to that of Example 8-(1). The object compound was purified by column chromatography on silica gel (300 g) using chloroform as an eluent to give 36.41 g of 1-methyl-5-phthalimidoacetyl-2-indolinone.

IR (Nujol) : 1770 (small), 1720, 1675 cm⁻¹

(2) 5-Aminoacetyl-1-methyl-2-indolinone hydrochloride (23.73 g) was obtained from the above object compound (36.0 g) of Example 9-(1) according to a similar manner to that of Example 8-(2).

IR (Nujol) : 3150 (shoulder), 3000 (shoulder),
1720 (shoulder), 1710, 1680 cm⁻¹

NMR (DMSO-d₆, δ) : 3.17 (3H, s), 3.63 (2H, s),
4.2-4.8 (2H, m), 7.10 (1H, d, J=8.0Hz),
7.7-8.1 (2H, m), 8.2-8.8 (2H, m)

(3) 5-Ethoxycarbonylaminoacetyl-1-methyl-2-indolinone (2.64 g) was obtained from the above object compound (4.8 g) of Example 9-(2) according to a similar manner to that of Example 8-(3).

IR (Nujol) : 3350, 3270, 3160, 1635, 1610 cm⁻¹


NMR (DMSO-d₆, δ) : 1.17 (3H, t, J=6.4Hz),
3.13 (3H, s), 3.59 (2H, s), 4.01 (2H, q,
J=6.4Hz), 4.45 (2H, d, J=6.0Hz), 6.9-7.4 (2H, m),
7.8-8.1 (2H, m)

(4) 6-(1-Methyl-2-indolinon-5-yl)-4,5-dihydro-1,2,4-triazin-3(2H)-one (1.14 g) was obtained from the object compound (2.56 g) of Example 9-(3) according to a similar manner to that of Example 8-(4).

5 mp : >300°C (recrystallized from a mixture of dimethylsulfoxide and methanol)
 IR (Nujol) : 3240, 3100, 1700, 1680 (shoulder)
 NMR (DMSO-d₆, δ) : 3.11 (3H, s), 3.55 (2H, s),
 4.24 (2H, d, J=1.8), 6.95 (1H, d, J=8.6Hz),
 10 7.17 (1H, br. s), 7.4-7.7 (2H, m),
 9.7-9.9 (1H, m)

Example 10

(1)




Propionyl chloride (67.2 g) was added dropwise to a mixture of 1-acetyl-1,2,3,4-tetrahydroquinoline (84 g) and aluminum chloride (169 g) over 1 hour with stirring, and the stirring was continued for 1 hour at room temperature and for 1.5 hours at 80°C. The mixture was dissolved in chloroform and then poured into ice water. The organic layer was separated, washed successively with water and an aqueous solution of sodium bicarbonate, dried over magnesium sulfate and evaporated. The oily residue was purified by column chromatography on silica gel (700 g) with a mixture of benzene and ethyl acetate (10:1) as an eluent to give an isomeric mixture of 6-and 7-propionyl-1-acetyl-1,2,3,4-tetrahydroquinoline (79.6 g).

35 NMR (CDCl₃, δ) : 1.19 (3H, t, J=7Hz),

Ca. 1.7-2.3 (2H, m), 2.26 (3H, s),
 2.80 (2H, t, J=6.2Hz), 2.96 (2H, q, J=7Hz),
 3.79 (2H, t, J=6.6Hz), 7.1-8.1 (3H, m)

5 (2)



15 The above obtained isomeric mixture compound (79.5 g) was dissolved in methylene chloride (240 ml) and the solution was saturated with hydrogen chloride. To the stirred solution was added dropwise iso-amyl nitrite (48.4 g) over a period of 1 hour. After stirring for 30 minutes, the solution was evaporated in vacuo and the oily residue was dissolved in methanol (100 ml), and stirred for 1 hour. The resultant solid was collected by filtration and recrystallized from methanol to give 1-acetyl-6-(2-hydroxyiminopropionyl)-1,2,3,4-tetrahydroquinoline (17.97 g).

25 IR (Nujol) : 3150, 3020, 1660, 1615, 1590 cm^{-1}
 NMR (DMSO-d_6 , δ) : Ca. 1.6-2.3 (2H, m), 2.01 (3H, s),
 2.20 (3H, s), 2.75 (2H, t, J=6.4Hz), 3.69 (2H, t, J=6Hz), 7.64 (3H, s), 12.25 (1H, s)


30 The above obtained filtrates were evaporated in vacuo to give a residue. The residue was dissolved in 10% aqueous solution of sodium hydroxide and then washed with diethyl ether and then acidified with conc. hydrochloric acid. The resultant oil was extracted with chloroform, washed with water, dried and evaporated.
 35 The oily residue was chromatographed on silica gel (200 g)

with a mixture of chloroform and ethyl acetate (10:1) as an eluent. The eluates were evaporated and the oily residue was triturated with diethyl ether to give 1-acetyl-7-(2-hydroxyiminopropionyl)-1,2,3,4-tetrahydroquinoline (22.67 g).

IR (Nujol) : 3120, 3010 (shoulder), 1645, 1620, 1590 cm^{-1}

NMR (DMSO-d_6 , δ) : Ca. 1.6-2.3 (2H, m), 2.01 (3H, s), 2.17 (3H, s), 2.76 (2H, t, $J=6.6\text{Hz}$), 3.67 (2H, t, $J=6.2\text{Hz}$), 7.25 (1H, d, $J=7.8\text{Hz}$), 7.55 (1H, dd, $J=1.8, 7.8\text{Hz}$), 7.98 (1H, d, $J=1.8\text{Hz}$), 12.29 (1H, s)

(3)



The above obtained 1-acetyl-6-(2-hydroxyiminopropionyl)-1,2,3,4-tetrahydroquinoline (17.5 g) was added to a suspension of thiosemicarbazide (6.2 g) in methanol (62 ml). To the solution was added saturated ethanolic solution of hydrogen chloride (1 ml), and then the mixture was refluxed for 40 minutes with stirring. After cooling, the resultant precipitates were collected by filtration, washed with methanol, and then dried to give 20.53 g of 1-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-hydroxyimino-1-propanone thiosemicarbazone.


IR (Nujol) : 3350, 3250, 3160, 1660, 1620 cm^{-1}

NMR (DMSO-d_6 , δ) : Ca. 1.7-2.1 (2H, m),

1.96 (s) } (3H), 2.19 (3H, s),
2.19 (s) }

2.75 (2H, t, J=6Hz), 3.72 (2H, t, J=6Hz),
 6.89-7.17 (1H, m), 7.43-7.79 (2H, m),
 8.1 (1H, b.s.), 8.53 (b.s.) } (2H), 11.73 (s) } (1H)
 10.63 (s) } (2H), 12.12 (s) }

5 (4)




10

Sodium bicarbonate (10.15 g) and water (100 ml) were added to a suspension of the above obtained compound of Example 10-(3) (20.13 g) in methanol (100 ml). The mixture was refluxed for 6 hours with stirring and filtered by suction. To the filtrate was added dropwise methyl iodide (9.43 g), stirred for 30 minutes at room temperature, and concentrated to a small volume. The residue was extracted with ethyl acetate and the extract was washed with water, dried over magnesium sulfate, and evaporated in vacuo. The oily residue was purified by column chromatography on silica gel (120 g) with a mixture of benzene and ethyl acetate (5:1) as an eluent to give 6-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-3-methylthio-1,2,4-triazine (13.86 g).

IR (film/NaCl) : 1655 cm^{-1}
 NMR (DMSO- d_6 , δ) : Ca. 1.7-2.2 (2H, m), 2.21 (3H, s),
 2.51 (3H, s), 2.63 (3H, s), 2.79 (2H, t, J=6.2Hz),
 3.74 (2H, t, J=6.4Hz), Ca. 7.3-7.8 (3H, m)

30

(5)



35

A mixture of the above obtained compound (11 g) of Example 10-(4) in 10% aqueous solution of potassium hydroxide (54 ml) and methanol (54 ml) was heated at 60°C for 30 minutes with stirring and allowed at room temperature. To the solution was added sodium borohydride (2.65 g), stirred for 1.5 hours at room temperature and acidified with conc. hydrochloric acid. The resultant precipitates were collected by filtration, washed with water, dried, and recrystallized from 70% aqueous ethanol to give 6-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (6.19 g).


mp: 241 to 245°C

IR (Nujol) : 3200, 3080, 1685, 1645 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.22 (3H, d, $J=7\text{Hz}$), Ca. 1.6-2.2 (2H, m), 2.21 (3H, s), 2.77 (2H, t, $J=6.4\text{Hz}$), 3.72 (2H, t, $J=6.4\text{Hz}$), 4.66 (1H; d, q; $J=3.6$, 7.0Hz), 7.43 (1H, b.s.), 7.54 (3H, s), 9.95 (1H, d, $J=1.2\text{Hz}$)

Anal. Calcd. for $\text{C}_{15}\text{H}_{18}\text{N}_4\text{O}_2$: C, 62.92; H, 6.34; N, 19.57
Found : C, 62.67; H, 6.31; N, 19.50

(6)



A suspension of the above obtained compound (5.32 g) of Example 10-(5) in 100% hydrazine hydrate (50 ml) was heated at 100°C for 13 hours. After cooling, the resultant precipitates were collected by filtration, washed with methanol, dried and recrystallized from 70% aqueous ethanol to give crystals of 6-(1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (4.27 g).


mp : 284 to 286°C

IR (Nujol) : 3400, 3200, 3060, 1685 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.16 (3H, d, $J=6.6\text{Hz}$),
 1.5-2.1 (2H, m), 2.68 (2H, t, $J=6.2\text{Hz}$),
 3.21 (2H, b.t., $J=5.2\text{Hz}$), 4.48 (1H; d, q;
 5 $J=2.6, 6.6\text{Hz}$), 6.02 (1H, b.s.), 6.41 (1H, d,
 $J=8.4\text{Hz}$), 7.0-7.4 (3H, m), 9.59 (1H, d, $J=2\text{Hz}$)

Anal. Calcd. for $\text{C}_{13}\text{H}_{16}\text{N}_4\text{O}$: C, 63.92; H, 6.60; N, 22.93
 Found: C, 63.92; H, 6.52; N, 22.85

10 Example 11: Synthesis of the compound of formula :



(1). 1-Acetyl-7-(2-hydroxyimino-1-thiosemicarbazono-propyl)-1,2,3,4-tetrahydroquinoline (22.03 g) was obtained
 20 from 1-acetyl-7-(2-hydroxyiminopropionyl)-1,2,3,4-tetrahydroquinoline (19.06 g) in a similar manner to that of Example 10(3).

IR (Nujol) : 3420, 3260, 3150, 1650, 1600 cm^{-1}
 NMR (DMSO-d_6 , δ) : Ca. 1.7-2.1 (2H, m), 1.97 (s) } (3H),
 25 2.19 (s) }
 2.19 (3H, s), 2.78 (2H, b.t., $J=6\text{Hz}$),
 3.72 (2H, t, $J=6\text{Hz}$), Ca. 6.8-7.7 (3H, m),
 8.09 (1H, b.s.), 8.56 (b.s.) } (2H),
 10.72 (s) }
 30 11.69 (s) } (1H)
 12.18 (s) }

(2) The reaction of the above obtained compound
 (21.43 g) of Example 11-(1) with sodium bicarbonate and
 methyl iodide was carried out according to a similar
 35 manner to that of Example 10-(4). An isolation of the

object compound was conducted as follows. The reaction mixture was evaporated to give a residue and extracted with ethyl acetate after addition of water. The extract was dried, evaporated and chromatographed on silica gel (80 g) with a mixture of benzene and ethyl acetate (5:1) as an eluent. The eluates was evaporated and the residue was triturated with methanol to give 6-(1-acetyl-1,2,3,4-tetrahydroquinolin-7-yl)-5-methyl-3-methylthio-1,2,4-triazine (9.29 g).

IR (Nujol) : 1650 cm^{-1}

NMR (DMSO- d_6 , δ) : Ca. 1.6-2.3 (2H, m), 2.23 (3H, s), 2.67 (3H, s), 2.83 (2H, t, $J=6.8\text{Hz}$), 3.76 (2H, t, $J=6\text{Hz}$), 7.38 (2H, b.s.), 7.82 (1H, b.s.)

(3) 6-(1-Acetyl-1,2,3,4-tetrahydroquinolin-7-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (7.37 g) was obtained from the above obtained compound (8.98 g) of Example 11(2) in a similar manner to that of Example 10-(5).

mp : $234\text{ to }240^\circ\text{C}$ (dec.) (from aqueous ethanol)

IR (Nujol) : 3340, 3280, 3150 (shoulder), 1705, 1690, 1610 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21 (3H, d, $J=6.8\text{Hz}$), Ca. 1.6-2.3 (2H, m), 2.18 (3H, s), 2.74 (2H, t, $J=6.4\text{Hz}$), 3.73 (2H, t, $J=7.2\text{Hz}$), 4.63 (1H; d, q; $J=3.6, 6.8\text{Hz}$), 7.21 (1H, d, $J=8.2\text{Hz}$), Ca. 7.4 (1H, b.s.), 7.49 (1H; d, d; $J=1.8, 8.2\text{Hz}$), 7.86 (1H, d, $J=1.8\text{Hz}$), 10.0 (1H, b.s.)

Anal. Calcd. for $C_{15}H_{18}N_4O_2$: C, 62.92; H, 6.34; N, 19.57
Found : C, 62.85; H, 6.30; N, 19.50

(4) 6-(1,2,3,4-Tetrahydroquinolin-7-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (4.36 g) was obtained from the above obtained compound (7.19 g) of Example 11-(3) according to a similar manner to that of Example 10-(6).


mp: $\sim 231\text{ to }238^\circ\text{C}$ (from 70% aqueous ethanol)

IR (Nujol) : 3420, 3210, 3090, 1695 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.18 (3H, d, $J=6.6\text{Hz}$), 1.5-2.1 (2H, m), 2.66 (2H, t, $J=6.2\text{Hz}$), 3.19 (2H, b.t., $J=6\text{Hz}$), 4.48 (1H; d, q; $J=3.4, 6.6\text{Hz}$), 5.68 (1H, b.s.), 6.6-7.0 (3H, m), 7.30 (1H, b.s.), 9.83 (1H; d, $J=1.8\text{Hz}$)

Anal. Calcd. for $\text{C}_{13}\text{H}_{16}\text{N}_4\text{O}$: C, 63.92; H, 6.60; N, 22.93
Found : C, 63.64; H, 6.53; N, 22.89

Example 12 : Synthesis of the compound of the formula :



(1) A solution of 1-methyl-2-oxo-6-propionyl-1,2,3,4-tetrahydroquinoline (20 g) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (20.9 g) in benzene (250 ml) was refluxed for 1 day. The mixture was filtered by suction and evaporated. The residue was chromatographed on silica gel (400 g) with a mixture of benzene and ethyl acetate (1:1) as an eluent. The eluates were concentrated to give an oil of 1-methyl-2-oxo-6-propionyl-1,2-dihydroquinoline (7.72 g).

(2) 6-(1-Methyl-2-oxo-1,2-dihydroquinolin-6-yl)-5-methyl-3-methylthio-1,2,4-triazine (1.19 g) was obtained from the above obtained compound (7.44 g) of Example 12-(1) according to a similar manner to that of Example 10-(2), (3) and (4).

NMR (CDCl_3 , δ) : 2.63 (3H, s), 2.74 (3H, s), 3.79 (3H, s), 6.77 (1H, d, $J=9.5\text{Hz}$), 7.50 (1H, d, $J=8.5\text{Hz}$), 7.64-8.06 (3H, m)

(3) 6-(1-Methyl-2-oxo-1,2-dihydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.71 g) was obtained from the above obtained compound (1.19 g) of Example 12-(2) in a similar manner to that of Example 10-(5).


mp : 293 to 296°C (from aqueous ethanol)

NMR (DMSO- d_6 , δ) : 1.24 (3H, d, $J=6.5\text{Hz}$),
3.63 (3H, s), 4.72 (1H; d, q; $J=3, 6.5\text{Hz}$),
6.64 (1H, d, $J=10\text{Hz}$), 7.35-7.67 (2H, m),
7.86-8.16 (3H, m), 9.98-10.13 (1H, m)

Anal. Calcd. for $C_{14}H_{14}N_4O_2$: C, 62.21; H, 5.22; N, 20.73

Found : C, 62.22; H, 5.19; N, 20.86

Example 13 : Synthesis of the compound of the formula :



Cyclopropanecarbonyl chloride (0.47 g) was added dropwise to a stirred solution of 6-(1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.73 g) and triethylamine (0.6 g) in N,N-dimethylformamide (7.3 ml) under ice cooling and the stirring was continued for 30 minutes. The solution was evaporated in vacuo and the residue was dissolved in chloroform. The solution was washed with diluted hydrochloric acid, dried, and evaporated. The residue was chromatographed on silica gel (5 g) using chloroform and then a mixture of chloroform and methanol (20:1) as an eluents. The eluates were evaporated in vacuo and the oily residue was crystallized from ethanol to give 6-(1-cyclopropanecarbonyl-1,2,3,4-tetrahydroquinolin-6-yl)-5-


methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.26 g).

mp: 215 to 219°C (dec.)

IR (Nujol) : 3210, 3090, 1700, 1655 cm^{-1}

NMR (DMSO-d_6 , δ) : Ca. 0.6-1.2 (4H, m), 1.23 (3H, d, $J=7\text{Hz}$), 1.7-2.2 (3H, m), 2.78 (2H, t, $J=6.4\text{Hz}$), 3.76 (2H, t, $J=6.4\text{Hz}$), 4.63 (1H; d, q; $J=3, 7\text{Hz}$), 7.40 (1H, b.s.), 7.50 (3H, b.s.), 9.91 (1H, d, $J=1.8\text{Hz}$)

Example 14 : Synthesis of the compound of the formula :



6-(1-Cyclobutanecarbonyl-1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.45 g) was obtained from 6-(1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.6 g) in a similar manner to that of Example 13..


mp: 247 to 251°C (from 70% aqueous ethanol)

IR (Nujol) : 3210, 3080, 1693, 1655 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.21 (3H, d, $J=6.6\text{Hz}$), 1.5-2.5 (6H, m), 2.5-3.0 (4H, m), 3.40 (1H, m), 3.66 (2H, m), 4.65 (1H, m), 7.3-7.7 (3H, m), 7.42 (1H, b.s.), 9.95 (1H, b.s.)

Anal Calcd. for $\text{C}_{18}\text{H}_{22}\text{N}_4\text{O}_2$: C, 66.24; H, 6.79; N, 17.17
Found :: C, 66.16; H, 6.85; N, 17.01

Example 15: Synthesis of the compound of the formula :




5

Sodium cyanoborohydride (0.19 g) was added portionwise to a suspension of 6-(1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.74 g), 36% aqueous formaldehyde (0.34 ml), acetic acid (1 ml) and methanol (3 ml) at room temperature. After stirring for 0.5 hours at the same temperature, the resultant precipitates were collected by filtration, washed with methanol, dried, and recrystallized from 70% aqueous ethanol to give 0.66 g of 6-(1-methyl-1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one.

mp : >255°C (dec.)
 IR (Nujol) : 3200, 3080, 1690 cm^{-1}
 NMR (DMSO- d_6 , δ) : 1.17 (3H, d, $J=6.4\text{Hz}$),
 1.6-2.2 (2H, m), Ca. 2.5-2.9 (2H, m), 2.85 (3H, s), 3.1-3.4 (2H, m), 4.3-4.8 (1H, m),
 6.53 (1H, d, $J=9.8\text{Hz}$), 7.1-7.5 (3H, m),
 9.63 (1H, b.s.)

Example 16 : Synthesis the compound of the formula :



30

(1) 1-Benzyl-6-(2-hydroxyiminopropionyl)-2-oxo-1,2,3,4-tetrahydroquinoline (5.45 g) was obtained from

35

1-benzyl-6-propionyl-2-oxo-1,2,3,4-tetrahydroquinoline (11.62 g) according to a similar manner to that of Example 10-(2).

IR (Nujol) : 3160 (broad), 1645, 1595 cm^{-1}

5 NMR (CDCl_3 , δ) : 2.13 (3H, s), 2.4-3.2 (4H, m),
5.13 (2H, s), 6.85 (1H, d, $J=9.6\text{Hz}$), 7.1-7.5
(5H, m), 7.6-7.9 (2H, m), 8.93 (1H, b.s.)

10 (2) 1-Benzyl-6-(2-hydroxyimino-1-thiosemicarbazono-propyl)-2-oxo-1,2,3,4-tetrahydroquinoline (6.73 g) (isomeric mixture) was obtained from the above object compound (5.31 g) of Example 16-(1) according to a similar manner to that of Example 10-(3).

IR (Nujol) : 3400, 3240, 3130, 1655, 1600 cm^{-1}

15 NMR (DMSO-d_6 , δ) : 1.91 (s) } (3H), Ca. 2.7-3.1 (4H, m),
2.1 (s) }
5.16 (2H, s), 6.8-7.8 (8H, m), 8.13 (1H, b.s.),
8.5 (2H, b.s.), 12.13 (s) } (1H)
11.73 (s) }

20 (3) 6-(1-Benzyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-3-methylthio-1,2,4-triazine (2.49 g) was obtained from the above object compound (6.6 g) of Example 16-(2) according to a similar manner to that of Example 10-(4).

25 NMR (CDCl_3 , δ) : 2.51 (3H, s), 2.66 (3H, s),
Ca. 2.7-3.3 (4H, m), 5.22 (2H, s),
6.97 (1H, d, $J=8.4\text{Hz}$), 7.1-7.6 (7H, m)

30 (4) 6-(1-Benzyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.92 g) was obtained from the above object compound (2.34 g) of Example 16-(3) according to a similar manner to that of Example 10-(5).

mp : 219 to 223°C (from methanol)


35 IR (Nujol) : 3200, 3080, 1705, 1685 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.17 (3H, d, $J=6.6\text{Hz}$),
 Ca. 2.6-3.3 (4H, m), 4.59 (1H; d, q; $J=3, 6.5\text{Hz}$),
 5.16 (2H, s), 6.90 (1H, d, $J=8.8\text{Hz}$), Ca. 7.1-7.8
 (8H, m), 9.90 (1H, d, $J=1.6\text{Hz}$)

5

Example 17: Synthesis the compound of the formula :

10



15

(1) 1-(2-Benzyloxyethyl)-6-(2-hydroxyiminopropionyl)-
 2-oxo-1,2,3,4-tetrahydroquinoline (9.19 g) was obtained
 from 1-(2-benzyloxyethyl)-6-propionyl-2-oxo-1,2,3,4-
 tetrahydroquinoline (32.4 g) according to a similar
 manner to that of Example 10-(2).

20

IR (Nujol) : 3250 (shoulder), 3160, 3020, 1640,
 1600 cm^{-1}

NMR (CDCl_3 , δ) : 2.15 (3H, s), 2.3-3.1 (4H, m),
 3.70 (2H, t, $J=5.5\text{Hz}$), 4.14 (2H, t, $J=5.5\text{Hz}$),
 4.47 (2H, s), 7.0-7.5 (6H, m), 7.7-8.0 (2H, m),
 Ca. 10.0 (1H, b.s.)

25

(2) 1-(2-Benzyloxyethyl)-6-(2-hydroxyimino-1-
 thiosemicarbazopropyl)-2-oxo-1,2,3,4-tetrahydroquinoline
 (8.99 g) (isomeric mixture) was obtained from the above
 object compound (8.98 g) of Example 17-(1) according to
 a similar manner to that of Example 10-(3).

30

IR (Nujol) : 3410, 3300, 3160, 1665, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : $\begin{matrix} 1.96 \text{ (s)} \\ 2.17 \text{ (s)} \end{matrix}$ (3H), Ca. 2.4-3.1 (4H, m),

35

~3.63 (2H; b.t., $J=5\text{Hz}$), 4.15 (2H; b.t., $J=5\text{Hz}$),

4.47 (s) } (2H), 6.92-7.5 (3H, m), 7.3 (5H, s),
 4.50 (s) }
 Ca. 8.0 (b.s.) } (1H), 8.13 (b.s.) } (2H),
 7.66 (b.s.) }
 12.1 (s) } (1H)
 11.69 (s) }

(3) 6-[1-(2-Benzoyloxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]-3-methylthio-5-methyl-1,2,4-triazine (6.81 g) was obtained from the above object compound (10.1 g) of Example 17(2) according to a similar manner to that of Example 10(4).

IR (film/NaCl) : 1675, 1610 cm^{-1}


NMR (CDCl_3 , δ) : 2.59 (3H, s), 2.72 (3H, s),
 Ca. 2.5-3.2 (4H, m), 3.79 (2H, t, $J=5.2\text{Hz}$),
 4.23 (2H, t, $J=5.2\text{Hz}$), 4.56 (2H, s), 7.29 (5H, s),
 7.3-7.7 (3H, m)

(4) 6-[1-(2-Benzoyloxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (3.92 g) was obtained from the above object compound (6.62 g) of Example 17(3) according to a similar manner to that of Example 10(5).

IR (Nujol) : 3220, 3100, 1685, 1645, 1620 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.21 (3H, d, $J=6.4\text{Hz}$),
 Ca. 2.4-2.8 (2H, m), 2.8-3.2 (2H, m),
 3.62 (2H, t, $J=5.4\text{Hz}$), 4.13 (2H, t, $J=5.4\text{Hz}$),
 4.48 (2H, s), Ca. 4.4-4.9 (1H, m), Ca. 7.1-7.8 (4H, m), 7.26 (5H, s), 9.93 (1H, d, $J=2\text{Hz}$)

Example 18: Synthesis the compound of the formula :



6-(1-Dimethylaminoacetamido-1,2,3,4-tetrahydroquinolin-6-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.42 g) was obtained by reacting the object compound (0.7 g) of Example 10-(6) with 2-dimethylaminoacetyl chloride hydrochloride (0.771 g) according to a similar manner to that of Example 13.

mp : 239 to 246°C


IR (Nujol) : 3200, 3100, 1690, 1655 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.20 (3H, d, $J=6.8\text{Hz}$),
 10 Ca. 1.5-2.3 (2H, m), 2.21 (6H, s), 2.76 (2H, b.t., $J=7\text{Hz}$), 3.29 (2H, s), 3.75 (2H, b.t., $J=6.6\text{Hz}$), 4.62 (1H; d, q; $J=3.6, 6.8\text{Hz}$), 7.40 (1H, br s), Ca. 7.4-7.8 (3H, m), 9.91 (1H, d, $J=2\text{Hz}$)

15 Anal. Calcd. for $\text{C}_{17}\text{H}_{23}\text{N}_5\text{O}_2$: C, 61.99; H, 7.04; N, 21.26
 Found : C, 61.73; H, 6.94; N, 21.30

Example 19.

20



25 (1) 6-(2-Hydroxyiminopropionyl)-1-methyl-3,4-dihydro-1H-2,1-benzothiazine 2,2-dioxide (2.6 g) was obtained from 1-methyl-6-propionyl-3,4-dihydro-1H-2,1-benzothiazine 2,2-dioxide (5.1 g) according to a similar manner to that of Example 4-(1).

30

mp : 178 to 180°C

IR (Nujol) : 3440, 1650, 1330, 1155, 1145 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.04 (3H, s), 3.00-3.68 (4H, m),
 3.27 (3H, s), 7.16 (1H, d, $J=8.5\text{Hz}$),
 7.79 (1H, br s), 7.83 (1H, dd, $J=8.5\text{Hz}, 2\text{Hz}$),
 35 12.34 (1H, s)

(2) 6-(2-Hydroxyimino-1-thiosemicarbazopropyl)-1-methyl-3,4-dihydro-1H-2,1-benzothiazine 2,2-dioxide (2.70 g) was obtained from the reaction product of Example 19-(1) (2.50 g) according to a similar manner to that of Example 1-(1).

mp : 227°C (dec.)

IR (Nujol) : 3460, 3340, 3125, 1610, 1340, 1155 cm^{-1}

NMR (DMSO- d_6 , δ) : 3.23 (3H, s), 3.32-3.80 (4H, m), 7.00-10.67 (6H, m), 1.95 (s) } 3H, 11.72 (s) } 1H
2.12 (s) }

(3) 6-(5-Methyl-3-methylthio-1,2,4-triazin-6-yl)-1-methyl-3,4-dihydro-1H-2,1-benzothiazine 2,2-dioxide (1.20 g) was obtained from the reaction product of Example 19-(2) (2.10 g) according to a similar manner to that of Example 4-(3).

mp : 162 to 164°C (recrystallized from ethyl acetate)

IR (Nujol) : 1345, 1160 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.50 (3H, s), 2.62 (3H, s), 3.27 (3H, s), 3.45-3.70 (4H, m), 7.20 (1H, d, J=8Hz), 7.57 (1H, d, J=2Hz), 7.62 (1H, dd, J=2Hz, 8Hz)

(4) 6-(5-Methyl-3-oxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-1-methyl-3,4-dihydro-1H-2,1-benzothiazine 2,2-dioxide (1.40 g) was obtained from the reaction product of Example 19-(3) (1.60 g) according to a similar manner to that of Example 4-(4).

mp : 291 to 293°C (recrystallized from a mixture of ethanol and N,N-dimethylformamide)

IR (Nujol) : 3225, 3075, 1700, 1350, 1165, 1130 cm^{-1}


NMR (DMSO- d_6 , δ) : 1.23 (3H, d, J=7Hz), 3.24 (3H, s), 3.27-3.64 (4H, m), 4.54-4.77 (1H, m), 7.12 (1H, d, J=9Hz), 7.43 (1H, br s), 7.61 (1H, br s), 7.64 (1H, d, J=9Hz), 9.96 (1H, d, J=2Hz)

Anal Calcd. for $C_{13}H_{16}N_4O_3S$:

C, 50.64; H, 5.23; N, 18.17

Found : C, 50.50; H, 5.36; N, 18.11

5 Example 20



(1) 5-(2-Hydroxyiminopropionyl)benzothiazolin-2-one (22.0 g) was obtained from 5-propionylbenzothiazolin-2-one (20.0 g) according to a similar manner to that of Example 4-(1).
15

mp : 238 to 240°C

IR (Nujol) : 3625, 3525, 3280, 3225, 3170, 1710 (sh),
1660 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.05 (3H, s), 7.18 (1H, d,
20 J=8Hz), 7.82 (1H, dd, J=8Hz, 2Hz), 8.10 (1H, d,
J=2Hz), 12.23 (1H, br s), 12.33 (1H, s)

(2) 5-(2-Hydroxyimino-1-thiosemicarbazonopropyl)-benzothiazolin-2-one (2.70 g) was obtained from the
25 reaction product of Example 20-(1) (3.00 g) according
to a similar manner to that of Example 1-(1).

mp : 244°C (dec.)

IR (Nujol) : 3340, 3260, 3175, 1710, 1670, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 7.03-8.58 (5H, m), 12.00 (1H,
30 br s), 2.00 (s) and 2.18 (s) (3H, 1:2),
8.80 (s) and 10.62 (s) (1H, 2:1),
11.68 (s) and 12.18 (s) (1H, 2:1)

(3) 5-(5-Methyl-3-methylthio-1,2,4-triazin-6-yl)-benzothiazolin-2-one (5.80 g) was obtained from the
35

reaction product of Example 20-(2) (16.8 g) according to a similar manner to that of Example 4-(3) provided that 1,8-diazabicyclo[5,4,0]undec-7-ene was used instead of potassium carbonate.

5 mp : 242 to 244°C
 IR (Nujol) : 3180, 1675, 1640 cm^{-1}
 NMR ($\text{DMSO}-d_6$, δ) : 2.63 (3H, s), 7.25 (1H, d, $J=8\text{Hz}$), 7.60 (1H, dd, $J=8\text{Hz}$, 2Hz), 7.90 (1H, d, $J=2\text{Hz}$), 12.00 (1H, br s)


10

(4) 5-(5-Methyl-3-oxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)benzothiazolin-2-one (4.75 g) was obtained from the reaction product of Example 20-(3) (5.70 g) according to a similar manner to that of Example 4-(4).

15 mp : 336 to 338°C (recrystallized from a mixture of N,N-dimethylformamide and ethanol)
 IR (Nujol) : 3230, 3090, 2700, 1720 (sh), 1690 cm^{-1}
 NMR ($\text{DMSO}-d_6$, δ) : 1.25 (3H, d, $J=7\text{Hz}$),
 20 4.58-4.85 (1H, m), 7.26 (1H, d, $J=9\text{Hz}$),
 7.53 (1H, s), 7.79 (1H, dd, $J=9\text{Hz}$, 2Hz),
 8.04 (1H, d, $J=2\text{Hz}$), 10.09 (1H, d, $J=2\text{Hz}$)
 Anal. Calcd. for $\text{C}_{11}\text{H}_{10}\text{N}_4\text{O}_2\text{S}$:
 C, 50.37; H, 3.84; N, 21.36
 25 Found : C, 50.75; H, 3.91; N, 21.42

Example 21

30



35

Ethyl bromoacetate (0.67 ml) was added dropwise to

0122494

a stirred solution of the object compound of Example 20-(4) (1.50 g) and potassium carbonate (0.83 g) in N,N-dimethylformamide (100 ml), and the stirring was continued for 2.5 hours at ambient temperature. The reaction mixture was evaporated in vacuo and the residue was dissolved in ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated to give 1.80 g of 3-ethoxycarbonylmethyl-5-(5-methyl-3-oxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)benzothiazolin-2-one.

mp : 200 to 202°C (recrystallized from acetone)

IR (Nujol) : 3230, 3190, 1748, 1710, 1690 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.22 (3H, t, J=8Hz),

1.24 (3H, d, J=8Hz), 4.18 (2H, q, J=8Hz),

4.48-4.72 (1H, m), 4.86 (2H, s),

7.34 (1H, d, J=9Hz), 7.43 (1H, s), 7.74 (1H,

dd, J=9Hz, 2Hz), 8.06 (1H, d, J=2Hz),


10.00 (1H, d, J=2Hz)

Anal. Calcd. for $\text{C}_{15}\text{H}_{16}\text{N}_4\text{O}_4\text{S}$

C, 51.72; H, 4.63, N, 16.08

Found : C, 51.65; H, 4.55, N, 16.07

Example 22




A mixture of the object compound of Example 21 (1.0 g) and 1-(2-hydroxyethyl)piperazine (1.2 g) was stirred for 4 hours at 120°C. After cooling, the reaction mixture was chromatographed on silica gel (45 g) by eluting

with a mixture of chloroform and methanol (9:1) to give 0.9 g of 3-[4-(2-hydroxyethyl)piperazin-1-yl-carbonylmethyl]-5-(5-methyl-3-oxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)benzothiazolin-2-one.

5 mp : 248 to 250°C (recrystallized from ethanol)
 IR (Nujol) : 3500, 3225, 3100, 1690, 1670, 1635 cm^{-1}
 NMR (DMSO- d_6 , δ) : 1.24 (3H, d, $J=8\text{Hz}$), Ca. 2.2-2.8
 (4H, m), 3.32-3.79 (8H, m), 4.39 (1H, t,
 10 $J=5\text{Hz}$), 4.52-4.74 (1H, m), 4.93 (2H, s),
 7.17 (1H, d, $J=8\text{Hz}$), 7.43 (1H, br s),
 7.72 (1H, dd, $J=8\text{Hz}$, 2Hz), 8.01 (1H, d, $J=2\text{Hz}$),
 9.98 (1H, d, $J=2\text{Hz}$)
 Anal. Calcd. for $\text{C}_{19}\text{H}_{24}\text{N}_6\text{O}_4\text{S}$
 C, 52.77; H, 5.59; N, 19.43
 15 Found : C, 52.66; H, 5.77; N, 19.19

Example 23

20



25


3-(2-Methoxyethyl)-5-(5-methyl-3-oxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)benzothiazolin-2-one (0.63 g) was obtained from the object compound of Example 20-(4) (0.70 g) and 2-bromoethyl methyl ether (0.25 ml) according to a similar manner to that of Example 21.

mp : 178 to 180°C (recrystallized from ethyl acetate)
 IR (Nujol) : 3225, 3075, 1700, 1685 cm^{-1}
 NMR (DMSO- d_6 , δ) : 1.17 (3H, d, $J=7\text{Hz}$), 3.31 (3H,
 35 s), 3.62 (2H, t, $J=5\text{Hz}$), 4.15 (2H, t, $J=5\text{Hz}$),

0122494

4.46-4.89 (1H, m), 7.38 (1H, d, J=8Hz),
 7.45 (1H, s), 7.73 (1H, dd, J=8Hz, 2Hz),
 8.01 (1H, d, J=2Hz), 10.01 (1H, d, J=2Hz)

5 Example 24



3-Methyl-5-(5-methyl-3-oxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)benzothiazolin-2-one (0.50 g) was obtained from the object compound of Example 20-(4) (0.70 g) and methyl iodide (0.17 ml) according to a similar manner to that of Example 21.

mp : 251 to 253°C.

IR (Nujol) : 3220, 3080, 1700, 1680 cm^{-1}


20 NMR (DMSO- d_6 , δ) : 1.23 (3H, d, J=7Hz),
 3.40 (3H, s), 4.47-4.85 (1H, m), 7.29 (1H, d, J=9Hz), 7.43 (1H, s), 7.75 (1H, dd, J=9Hz, 2Hz), 8.00 (1H, d, J=2Hz), 10.00 (1H, d, J=2Hz)

Anal. Calcd. for $\text{C}_{12}\text{H}_{12}\text{N}_4\text{O}_2\text{S}$:

C, 52.16; H, 4.38; N, 20.28

25 Found : C, 51.21; H, 4.56; N, 19.92

Example 25



35

3-Isopropyl-5-(5-methyl-3-oxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)benzothiazolin-2-one (0.38 g) was obtained from the object compound of Example 20-(4) (0.80 g) and isopropyl iodide (0.30 ml) according to a similar manner to that of Example 21.

mp : 214 to 216°C (recrystallized from a mixture of ethanol and n-hexane)

IR (Nujol) : 3225, 3080, 1710, 1690, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.23 (3H, d, J=7Hz),

1.50 (6H, d, J=7Hz), 4.48-5.03 (2H, m),
7.43 (1H, br s), 7.50 (1H, d, J=8.5Hz),
7.74 (1H, dd, J=8.5Hz, 2Hz), 8.02 (1H, d, J=2Hz), 10.02 (1H, d, J=2Hz)

Anal. Calcd. for $\text{C}_{14}\text{H}_{16}\text{N}_4\text{O}_2\text{S}$

C, 55.25; H, 5.30; N, 18.41

Found : C, 55.38; H, 5.23; N, 18.57

1. A compound of the formula

$$\begin{array}{c}
 \text{R}^1 \quad \text{N}-\text{N}-\text{R}^2 \\
 \diagdown \quad \diagup \\
 \text{C}=\text{C} \\
 \diagup \quad \diagdown \\
 \text{R}^4 \quad \text{N}=\text{O} \\
 \diagdown \quad \diagup \\
 \quad \quad \text{R}^3
 \end{array}$$


R¹ is a 1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2-dihydroquinolyl,
indolyl,
2-oxoindolinyl,
benzothiazolyl,
2-oxobenzothiazolinyl,
3,4-dihydro-1H-2,1-benzothiazinyl in which the
S atom being optionally oxidized, or
3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl,
each of which may have one or more substituent(s)
selected from lower alkyl, hydroxy(lower)alkyl,
lower alkylamino, lower alkanoyl, cyclic lower
alkanoyl, lower alkoxy(lower)alkyl, lower
alkylamino(lower)alkanoyl, benzyl, benzyloxy(lower)-
alkyl, lower alkoxycarbonyl(lower)alkyl and
4-(2-hydroxyethyl)piperazin-1-yl-carbonylmethyl;
R² is a hydrogen, lower alkenyl, benzyl, carboxy(lower)-
alkyl or lower alkoxycarbonyl(lower)alkyl;
R³ and R⁴, which may be the same or different, are each
hydrogen or lower alkyl or together represent a
bond;

provided that when R¹ is 2-oxo-1,2,3,4-tetrahydroquinolyl
which is unsubstituted or substituted by a lower alkyl,
35 then, R⁴ is a hydrogen or R² is a lower alkenyl, benzyl,

carboxy(lower)alkyl or lower alkoxycarbonyl(lower)alkyl;
and pharmaceutically acceptable salt thereof.

2. A compound of claim 1,
5 wherein R¹ is a 1,2,3,4-tetrahydroquinolyl which may have one or more substituent(s) selected from lower alkyl, lower alkanoyl, cyclic lower alkanoyl and lower alkylamino(lower)alkanoyl.
- 10 3. A compound of claim 1,
wherein R¹ is a 2-oxo-1,2,3,4-tetrahydroquinolyl which is substituted with a lower alkyl; R² is a lower alkenyl, benzyl, carboxy(lower)alkyl or lower alkoxycarbonyl(lower)alkyl.
- 15 4. A compound of claim 1,
wherein R¹ is a 2-oxo-1,2,3,4-tetrahydroquinolyl which is substituted with a lower alkyl and R², R³ and R⁴ are each hydrogen.
- 20 5. The compound according to claim 4, which is
6-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-
4,5-dihydro-1,2,4-triazin-3(2H)-one.
- 25 6. A compound of claim 1,
wherein R¹ is a 2-oxo-1,2,3,4-tetrahydroquinolyl which is substituted with a hydroxy(lower)alkyl.
- 30 7. A compound of claim 1,
wherein R¹ is a 2-oxo-1,2-dihydroquinolyl which may be substituted with a lower alkyl.
- 35 8. The compound according to claim 7, which is
6-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-5-
methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one.

9. A compound of claim 1,
wherein R^1 is a indolyl which may be substituted
with one or more lower alkyl(s).
- 5 10. A compound of claim 1,
wherein R^1 is a 2-oxoindolinyl which may be
substituted with a lower alkyl.
- 10 11. A compound of claim 1,
wherein R^1 is a benzothiazolyl which may be
substituted with a lower alkylamino.
- 15 12. A compound of claim 1,
wherein R^1 is a 2-oxobenzothiazolinyl which may have
one or more substituent(s) selected from lower alkyl,
lower alkoxy(lower)alkyl, lower alkoxycarbonyl(lower)-
alkyl and 4-(2-hydroxyethyl)piperazin-1-yl-
carbonylmethyl.
- 20 13. A compound of claim 1,
wherein R^1 is a 3,4-dihydro-1H-2,1-benzothiazinyl
in which the S atom being optionally oxidized.
- 25 14. A compound of claim 1,
wherein R^1 is a 3-oxo-2,3-dihydro-4H-1,4-
benzoxazinyl which may be substituted with a lower
alkyl.
- 30 15. A process for preparing a compound of the formula




wherein

R^1 is a 1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 5 indolyl,
 2-oxoindolinyl,
 benzothiazolyl,
 2-oxobenzothiazolinyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in which the
 10 S atom being optionally oxidized, or
 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl,
 each of which may have one or more substituent(s)
 selected from lower alkyl, hydroxy(lower)alkyl,
 lower alkylamino, lower alkanoyl, cyclic lower
 15 alkanoyl, lower alkoxy(lower)alkyl,
 lower alkylamino(lower)alkyl, benzyl
 benzyloxy(lower)alkyl, lower alkoxy-carbonyl-
 (lower)alkyl and
 4-(2-hydroxyethyl)piperazin-1-yl-carbonylmethyl;
 20 R^2 is a hydrogen, lower alkenyl, benzyl, carboxy(lower)-
 alkyl or lower alkoxy-carbonyl(lower)alkyl;
 R^3 and R^4 , which may be the same or different, are each
 hydrogen or lower alkyl or together represent
 a bond;

25 provided that when R^1 is 2-oxo-1,2,3,4-tetrahydroquinolyl
 which is unsubstituted or substituted by a lower alkyl,
then, R^4 is a hydrogen or R^2 is a lower alkenyl, benzyl,
 carboxy(lower)alkyl or lower alkoxy-carbonyl(lower)alkyl;
 and pharmaceutically acceptable salt thereof, which
 30 comprises


(1) by reacting a compound of the formula [II]



(wherein R^1 is as defined above; and

R_a^4 is a hydrogen or lower alkyl)

or its salt with a compound of the formula [III]




5 (wherein R_a^2 is a lower alkenyl, benzyl, carboxy(lower)-alkyl or lower alkoxy(alkyl)-alkyl; and

Y is an acid residue)

or its salt to provide a compound of the formula [Ia]

10



[Ia]


15

(wherein R^1 , R_a^2 and R_a^4 are each as defined above)

or its salt, or

(2) by reducing a compound of the formula [Ia]

20




[Ia]

25

(wherein R^1 , R_a^2 and R_a^4 are each as defined above)

or its salt to provide a compound of the formula [Ib]

30




[Ib]

35


(wherein R^1 , R_a^2 and R_a^4 are each as defined above), or

(3) by treating a compound of the formula [IV]




(wherein R^1 and R_a^4 are each as defined above; and
 Z is a leaving group)

10 with a base and then by reducing to provide a compound
of the formula




(wherein R^1 and R_a^4 are each as defined above) or its salt,
or

20 (4) by solvolysis of a compound of the formula [Id]



(wherein R^1 , R^3 and R_a^4 are each as defined above; and
 R_b^2 is a lower alkoxy carbonyl(lower)alkyl)
or its salt to provide a compound of the formula [Ie]




0122494

(wherein R^1 , R^3 and R^4 are each as defined above; and
 R_C^2 is a carboxy(lower)alkyl)

or its salt, or

(5) by alkylation of a compound of the formula [If]

5




10

[If]

(wherein R^1 , R^2 and R_a^4 are each as defined above)

or its salt to provide a compound of the formula [Ig]

15



[Ig]


20

(wherein R^1 , R^2 and R_a^4 are each as defined above; and
 R_a^3 is a lower alkyl)

or its salt, or

(6) by subjecting a compound of the formula [Ih]

25



[Ih]

30

(wherein R^2 , R^3 and R^4 are each as defined above; and
 R_a^1 is a 1,2,3,4-tetrahydroquinolyl,


2-oxo-1,2,3,4-tetrahydroquinolyl,

2-oxo-1,2-dihydroquinolyl,

35

indolyl,

2-oxoindolinyl,
 benzothiazolyl,
 2-oxobenzothiazolinyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in
 5 which the S atom being optionally oxidized,
 or
 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
 each of which has at least one substituent
 selected from lower alkanoyl, cyclic lower
 10 alkanoyl and benzyloxy(lower)alkyl)
 or its salt to an elimination reaction of the protective
 group to provide a compound of the formula [Ii]




20 (wherein R^2 , R^3 and R^4 are each as defined above; and
 R^1_b is a 1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 indolyl,
 25 2-oxoindolinyl,
 benzothiazolyl,
 2-oxobenzothiazolinyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in which
 the S atom being optionally oxidized, or
 30 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, and
 each of which may be substituted with a
 hydroxy(lower)alkyl)

or its salt, or

(7) by subjecting a compound of the formula

35


5



10

(wherein R^2 , R^3 and R^4 are each as defined above;
 R^5 is a hydrogen or lower alkyl; and
 R^6 is a hydrogen or lower alkyl)
or its salt to a Fischer Indole Synthesis or chemically
equivalent thereto to provide a compound of the formula
[Ij]


15



20

(wherein R^2 , R^3 , R^4 , R^5 and R^6 are each as defined above)
or its salt, or
(8) by a cyclization of a compound of the formula [VI]


25



30

(wherein R^2 , R^3 and R^4 are each as defined above; and
 R^7 is a lower alkylamino)
or its salt to provide a compound of the formula [Ik]


35



[Ik]

(wherein R^2 , R^3 , R^4 and R^7 are each as defined above)
or its salt, or


10 (9) by subjecting a compound of the formula [VII]



[VII]

(wherein R^1 and R_a^3 are each as defined above)

15 or its salt with hydrazine hydrate to provide a
compound of the formula [II]




[II]

(wherein R^1 is as defined above)

or its salt, or

(10) by acylation of a compound of the formula [Im]



[Im]


(wherein R^2 , R^3 and R^4 are each as defined above, and

R_c^1 is a 1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2-dihydroquinolyl,

35

indolyl,
2-oxoindoliny1,
benzothiazolyl,
2-oxobenzothiazoliny1,
5 3,4-dihydro-1H-2,1-benzothiaziny1 in
which the S atom being optionally
oxidized, or
3-oxo-2,3-dihydro-4H-1,4-benzoxaziny1)
or its salt to provide a compound of the formula [In]

10



15

[In]
(wherein R^2 , R^3 and R^4 are each as defined above; and
 R_d^1 is a 1,2,3,4-tetrahydroquinolyl,

20

2-oxo-1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2-dihydroquinolyl,
indolyl,
2-oxoindoliny1,
benzothiazolyl,
2-oxobenzothiazoliny1,
3,4-dihydro-1H-2,1-benzothiaziny1 in
which the S atom being optionally
oxidized, or
3-oxo-2,3-dihydro-4H-1,4-benzoxaziny1,
and


25

each of which has at least one substituent
selected from lower alkanoyl, cyclic
lower alkanoyl, and lower alkylamino-
(lower)alkanoyl)

30

or its salt, or
(11) by alkylating a compound of the formula [Im]

35




5

[Im]

(wherein R_C^1 , R^2 , R^3 and R^4 are each as defined above)
or its salt to provide a compound of the formula [Ip]

10



[Ip]

15

(wherein R^2 , R^3 and R^4 are each as defined above; and
 R_e^1 is a 1,2,3,4-tetrahydroquinolyl,

2-oxo-1,2,3,4-tetrahydroquinolyl,

2-oxo-1,2-dihydroquinolyl,

indolyl,

20

2-oxoindolyl,

benzothiazolyl,

2-oxobenzothiazolyl,

3,4-dihydro-1H-2,1-benzothiazinyl in

which the S atom being optionally

25

oxidized, or

3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl,

and

each of which is substituted with a

lower alkyl, hydroxy(lower)alkyl, lower

30

alkoxy(lower)alkyl, benzyl, benzyloxy-

(lower)alkyl, lower alkoxycarbonyl-

(lower)alkyl and


4-(2-hydroxyethyl)piperazin-1-yl-

carbonylmethyl)

35

or its salt, or

(12) by reacting a compound of the formula [Iq]




[Iq]

(wherein R^2 , R^3 and R^4 are each as defined above; and

R^1_f is a 1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2,3,4-tetrahydroquinolyl,
 2-oxo-1,2-dihydroquinolyl,
 indolyl,
 2-oxoindolinyl,
 benzothiazolyl,
 2-oxobenzothiazolinyl,
 3,4-dihydro-1H-2,1-benzothiazinyl in
 which the S atom being optionally
 oxidized, or
 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl,
 and
 each of which is substituted with a
 lower alkoxy carbonyl(lower)alkyl)

or its salt with 1-(2-hydroxyethyl)piperazine to
 provide a compound of the formula



[Ir]

(wherein R^2 , R^3 and R^4 are each as defined above; and

R^1_g is a 1,2,3,4-tetrahydroquinolyl,

2-oxo-1,2,3,4-tetrahydroquinolyl,
2-oxo-1,2-dihydroquinolyl,
indolyl,
2-oxoindolyl,
5 benzothiazolyl,
2-oxobenzothiazolyl,
3,4-dihydro-1H-2,1-benzothiazinyl in
which the S atom being optionally
oxidized, or
10 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl,
and
each of which is substituted with a
4-(2-hydroxyethyl)piperazin-1-yl-
carbonylmethyl)
15 or its salt.

16. A pharmaceutical composition comprising a compound
of claim 1 for treating hypertension, thrombosis
and(or) ulcer.
- 20 17. A method for treating hypertension, thrombosis and
(or) ulcer which comprises administering a
pharmaceutically effective amount of a compound of
claim 1.

25

30

35